WO2020056410A1 - Compositions and methods for modulating immunosuppression - Google Patents
Compositions and methods for modulating immunosuppression Download PDFInfo
- Publication number
- WO2020056410A1 WO2020056410A1 PCT/US2019/051298 US2019051298W WO2020056410A1 WO 2020056410 A1 WO2020056410 A1 WO 2020056410A1 US 2019051298 W US2019051298 W US 2019051298W WO 2020056410 A1 WO2020056410 A1 WO 2020056410A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tryptophan
- metabolic breakdown
- breakdown product
- product
- analog
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 29
- 230000001506 immunosuppresive effect Effects 0.000 title abstract description 19
- 206010062016 Immunosuppression Diseases 0.000 title abstract description 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 46
- 238000011282 treatment Methods 0.000 claims abstract description 32
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 15
- YGPSJZOEDVAXAB-UHFFFAOYSA-N (R)-Kynurenine Natural products OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims description 142
- 230000015556 catabolic process Effects 0.000 claims description 83
- 230000002503 metabolic effect Effects 0.000 claims description 82
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 56
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 51
- 239000003018 immunosuppressive agent Substances 0.000 claims description 40
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 37
- 230000001861 immunosuppressant effect Effects 0.000 claims description 34
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 26
- 229930182827 D-tryptophan Natural products 0.000 claims description 22
- 210000003289 regulatory T cell Anatomy 0.000 claims description 21
- 230000000747 cardiac effect Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 230000007052 brain toxicity Effects 0.000 claims description 13
- 231100000976 cerebrotoxicity Toxicity 0.000 claims description 13
- 238000007912 intraperitoneal administration Methods 0.000 claims description 13
- 210000003734 kidney Anatomy 0.000 claims description 12
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 11
- 230000000961 alloantigen Effects 0.000 claims description 11
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 11
- 229960001967 tacrolimus Drugs 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 9
- 230000001988 toxicity Effects 0.000 claims description 8
- 231100000419 toxicity Toxicity 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 231100000433 cytotoxic Toxicity 0.000 claims description 6
- 230000001472 cytotoxic effect Effects 0.000 claims description 6
- 208000024908 graft versus host disease Diseases 0.000 claims description 6
- 230000008629 immune suppression Effects 0.000 claims description 6
- 229960004618 prednisone Drugs 0.000 claims description 6
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 5
- 229960002930 sirolimus Drugs 0.000 claims description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 5
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 230000001926 lymphatic effect Effects 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 102000000521 Immunophilins Human genes 0.000 claims description 2
- 108010016648 Immunophilins Proteins 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 4
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 238000002650 immunosuppressive therapy Methods 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000009134 cell regulation Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 38
- YGPSJZOEDVAXAB-MRVPVSSYSA-N D-kynurenine Chemical compound OC(=O)[C@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-MRVPVSSYSA-N 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 230000004584 weight gain Effects 0.000 description 16
- 235000019786 weight gain Nutrition 0.000 description 16
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 14
- 239000002207 metabolite Substances 0.000 description 14
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000003915 cell function Effects 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 231100000331 toxic Toxicity 0.000 description 11
- 239000008103 glucose Substances 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000011740 C57BL/6 mouse Methods 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 108010029485 Protein Isoforms Proteins 0.000 description 9
- 102000001708 Protein Isoforms Human genes 0.000 description 9
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 8
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 8
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 8
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 235000014966 Eragrostis abyssinica Nutrition 0.000 description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 7
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- VCKPUUFAIGNJHC-UHFFFAOYSA-N 3-hydroxykynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC(O)=C1N VCKPUUFAIGNJHC-UHFFFAOYSA-N 0.000 description 6
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 6
- 230000033540 T cell apoptotic process Effects 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- -1 8-Metoxy-kurenate Chemical compound 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108010031676 Kynureninase Proteins 0.000 description 5
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 5
- 108010041191 Sirtuin 1 Proteins 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 210000003162 effector t lymphocyte Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000004129 fatty acid metabolism Effects 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000034659 glycolysis Effects 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 102000005447 kynureninase Human genes 0.000 description 5
- 230000037353 metabolic pathway Effects 0.000 description 5
- 229940049964 oleate Drugs 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- GZCGUPFRVQAUEE-AEKYUDOOSA-N D-glucose-(13)C6 Chemical compound O[13CH2][13C@@H](O)[13C@@H](O)[13C@H](O)[13C@@H](O)[13CH]=O GZCGUPFRVQAUEE-AEKYUDOOSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 4
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- WJXSWCUQABXPFS-UHFFFAOYSA-N 3-hydroxyanthranilic acid Chemical compound NC1=C(O)C=CC=C1C(O)=O WJXSWCUQABXPFS-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 description 3
- 108010033242 Kynurenine 3-monooxygenase Proteins 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000004136 fatty acid synthesis Effects 0.000 description 3
- 230000002414 glycolytic effect Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 101710120841 Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102100037652 Kynurenine 3-monooxygenase Human genes 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- NCIKQJBVUNUXLW-UHFFFAOYSA-N N-methyltryptamine Chemical compound C1=CC=C2C(CCNC)=CNC2=C1 NCIKQJBVUNUXLW-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 2
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001904 diabetogenic effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000008344 egg yolk phospholipid Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- CKAXPTWYSHDIBN-UHFFFAOYSA-N formyl-5-hydroxykynurenamine Chemical compound NCCC(=O)C1=CC(O)=CC=C1NC=O CKAXPTWYSHDIBN-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000009675 homeostatic proliferation Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000002480 immunoprotective effect Effects 0.000 description 2
- 210000002602 induced regulatory T cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OBFAPCIUSYHFIE-UHFFFAOYSA-N (5-hydroxyindol-3-yl)acetaldehyde Chemical compound OC1=CC=C2NC=C(CC=O)C2=C1 OBFAPCIUSYHFIE-UHFFFAOYSA-N 0.000 description 1
- JESMSCGUTIEROV-RTWAVKEYSA-N (5as,6r,9s,9as)-1-oxo-6-propan-2-ylspiro[3,5a,6,7,8,9a-hexahydro-2-benzoxepine-9,2'-oxirane]-4-carboxylic acid Chemical compound C([C@@H]([C@@H]1[C@@H]2C(OCC(=C1)C(O)=O)=O)C(C)C)C[C@]12CO1 JESMSCGUTIEROV-RTWAVKEYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- QCGTZPZKJPTAEP-NWJCXACMSA-N 2-Aminomuconate semialdehyde Natural products O=C(O)/C(/N)=C/C=C\C=O QCGTZPZKJPTAEP-NWJCXACMSA-N 0.000 description 1
- ZGQVEYFFYPOUKD-UHFFFAOYSA-N 2-Formaminobenzoylacetate Chemical compound OC(=O)CC(=O)C1=CC=CC=C1NC=O ZGQVEYFFYPOUKD-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- QCGTZPZKJPTAEP-REDYYMJGSA-N 2-aminomuconic 6-semialdehyde Chemical compound OC(=O)C(/N)=C\C=C/C=O QCGTZPZKJPTAEP-REDYYMJGSA-N 0.000 description 1
- ACERFIHBIWMFOR-UHFFFAOYSA-N 2-hydroxy-3-[(1-hydroxy-2-methylpropan-2-yl)azaniumyl]propane-1-sulfonate Chemical compound OCC(C)(C)NCC(O)CS(O)(=O)=O ACERFIHBIWMFOR-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- JTYMXXCJQKGGFG-UHFFFAOYSA-N 3-(imidazol-1-yl)lactic acid Chemical compound OC(=O)C(O)CN1C=CN=C1 JTYMXXCJQKGGFG-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 1
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 1
- VCKPUUFAIGNJHC-LURJTMIESA-N 3-hydroxy-L-kynurenine Chemical compound NC1=C(O)C=CC=C1C(=O)C[C@H]([NH3+])C([O-])=O VCKPUUFAIGNJHC-LURJTMIESA-N 0.000 description 1
- YCJNYHCCOXVYAF-UHFFFAOYSA-N 4-(2-amino-3-hydroxyphenyl)-2,4-dioxobutanoic acid Chemical compound NC1=C(O)C=CC=C1C(=O)CC(=O)C(O)=O YCJNYHCCOXVYAF-UHFFFAOYSA-N 0.000 description 1
- XNPKNHHFCKSMRV-UHFFFAOYSA-N 4-(cyclohexylamino)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCNC1CCCCC1 XNPKNHHFCKSMRV-UHFFFAOYSA-N 0.000 description 1
- LOJNFONOHINEFI-UHFFFAOYSA-N 4-[4-(2-hydroxyethyl)piperazin-1-yl]butane-1-sulfonic acid Chemical compound OCCN1CCN(CCCCS(O)(=O)=O)CC1 LOJNFONOHINEFI-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- VTOWJTPBPWTSMK-UHFFFAOYSA-N 4-morpholin-4-ylbutane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1CCOCC1 VTOWJTPBPWTSMK-UHFFFAOYSA-N 0.000 description 1
- DUUGKQCEGZLZNO-UHFFFAOYSA-M 5-Hydroxyindoleacetate Chemical compound OC1=CC=C2NC=C(CC([O-])=O)C2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-M 0.000 description 1
- LFUCRBSGQMAKCO-UHFFFAOYSA-N 5-hydroxyindoleacetylglycine Chemical compound C1=C(O)C=C2C(CC(=O)NCC(=O)O)=CNC2=C1 LFUCRBSGQMAKCO-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 101150035093 AMPD gene Proteins 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- FSBKJYLVDRVPTK-UHFFFAOYSA-N Cinnavalininate Chemical compound C1=CC=C2OC3=CC(=O)C(N)=C(C(O)=O)C3=NC2=C1C(O)=O FSBKJYLVDRVPTK-UHFFFAOYSA-N 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 241000508725 Elymus repens Species 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 1
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229930189936 Glyoxalase Natural products 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- JESMSCGUTIEROV-UHFFFAOYSA-N Heptelidic acid Natural products C1=C(C(O)=O)COC(=O)C2C1C(C(C)C)CCC12CO1 JESMSCGUTIEROV-UHFFFAOYSA-N 0.000 description 1
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- ACZFBYCNAVEFLC-UHFFFAOYSA-N Imidazole lactic acid Natural products OC(=O)C(O)CC1=CN=CN1 ACZFBYCNAVEFLC-UHFFFAOYSA-N 0.000 description 1
- 206010021818 Infection in an immunocompromised host Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010061224 Limb discomfort Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
- MVAWJSIDNICKHF-UHFFFAOYSA-N N-acetylserotonin Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CNC2=C1 MVAWJSIDNICKHF-UHFFFAOYSA-N 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 description 1
- LLLPDUXGHXIXIW-UHFFFAOYSA-N N-formylanthranilic acid Chemical compound OC(=O)C1=CC=CC=C1NC=O LLLPDUXGHXIXIW-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- LCTONWCANYUPML-VMIGTVKRSA-N Pyruvic-13C3 acid Chemical compound [13CH3][13C](=O)[13C](O)=O LCTONWCANYUPML-VMIGTVKRSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108700016257 Tryptophan 2,3-dioxygenases Proteins 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 210000000617 arm Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000006860 carbon metabolism Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- KACPVQQHDVBVFC-OIFXTYEKSA-N cis,cis-2-amino-3-(3-oxoprop-1-enyl)but-2-enedioic acid Chemical compound OC(=O)C(/N)=C(/C(O)=O)\C=C/C=O KACPVQQHDVBVFC-OIFXTYEKSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- DZHFTEDSQFPDPP-QTNFYWBSSA-L disodium;(2s)-2-hydroxypentanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CCC([O-])=O DZHFTEDSQFPDPP-QTNFYWBSSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000037447 lactate metabolism Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 208000001118 melena Diseases 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- MTUIFOCORDEJRB-UHFFFAOYSA-N n-methylserotonin Chemical compound C1=CC(O)=C[C]2C(CCNC)=CN=C21 MTUIFOCORDEJRB-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- ASUSBMNYRHGZIG-UHFFFAOYSA-N omega-N-Methylserotonin Natural products C1=C(O)C=C2C(CCNC)=CNC2=C1 ASUSBMNYRHGZIG-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940075065 polyvinyl acetate Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- XFALURCRIGINGT-UHFFFAOYSA-N quinoline-4,6-diol Chemical compound N1=CC=C(O)C2=CC(O)=CC=C21 XFALURCRIGINGT-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- FBZONXHGGPHHIY-UHFFFAOYSA-N xanthurenic acid Chemical compound C1=CC=C(O)C2=NC(C(=O)O)=CC(O)=C21 FBZONXHGGPHHIY-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Definitions
- This invention relates the fields of T cell regulation and therapeutic immunosuppression. More specifically, the invention provides compositions and methods for selective
- immunosuppressive therapies for the treatment of autoimmune diseases and allograft recipients .
- Therapeutic immunosuppression is required for many medical conditions ranging from autoimmune diseases to transplantation. 1 6
- current immunosuppressive medications are limited by non- specificity and toxicities, 7, 8 and more precise and safer drugs are needed.
- organ transplantation is potentially curative for patients suffering from organ failure; however, transplanted allografts require ongoing immunosuppression to prevent rejection.
- Current immunosuppressive medications are fairly effective at preventing acute allograft rejection, but are often associated with substantial toxicity.
- Prednisone induces weight gain, hypertension, and hyperglycemia, while tacrolimus causes renal toxicity, hypertension, and can induce diabetes, to name but a few complications associated with current therapies.
- TME tumor microenvironment
- Treg regulatory T cells
- the present invention provides a method of modulating immune suppression mediated by T cells (for example, by mediating proliferation or viability or apoptosis or cell death of T cells, or conventional T cells, or mature T cells, or cytotoxic T cells, or effector T cells, or regulatory T cells) in a subject, the method including administering to the subject a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of D-tryptophan, in an amount effective to suppress undesirable immune responses.
- the product is D-kynurneine.
- D-kynurneine is preferred over L-kynumeine as D-kynurneine does not exhibit the brain toxicity observed when L-kynumeine is administered.
- the invention provides a method for the treatment of autoimmune disease in a subject in need thereof, the method including administering to the subject a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan, and optionally, one or more alloantigens present in the allograft, wherein said product is D-kynurneine.
- the present invention also includes a method of preventing allograft rejection in a subject, the method including administering to the subject a metabolic breakdown product of D- tryptophan, or an analog of a metabolic breakdown product of D-tryptophan, and optionally, one or more alloantigens present in the allograft, wherein said product is D-kynurneine.
- the present invention also includes a method of preventing graft versus host disease in a recipient, the method including administering to the donor a metabolic breakdown product of D- tryptophan, or an analog of a metabolic breakdown product of D-tryptophan, and one or more alloantigens present in the recipient, wherein the metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of D-tryptophan, and the one or more
- alloantigens present in the recipient are administered to the donor prior to obtaining donor cells from the donor; obtaining donor cells from the donor; and administering the donor cells to the recipient.
- compositions comprising at least one metabolic breakdown product of D-tryptophan, and/or an analog of a metabolic breakdown product of tryptophan, for use in the methods and uses described.
- the product is D-kynurneine.
- the composition further comprises an immunosuppressant which is not a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan.
- the methods and compositions disclosed herein may be used along with an immunosuppressant other than the metabolic breakdown product of tryptophan or an analog a metabolic breakdown product of tryptophan.
- the metabolic breakdown product is D-kynurneine.
- the metabolic breakdown product of tryptophan or an analog thereof reduces dose of the immunosuppressant and/or administration frequency of the immunosuppressant for the subject compared to a regimen utilizing the immunosuppressant only without the metabolic breakdown product of tryptophan or an analog thereof.
- the metabolic breakdown product of tryptophan or an analog thereof alleviates/mitigates toxicity of the immunosuppressant.
- the metabolic breakdown product of tryptophan or an analog thereof improves specificity of the immunosuppressant while preserving the subject’s ability to fight infections and cancer.
- Figure 1 provides results of a Kynurenine regulatory T (Treg) cells suppression assay.
- Purified CD4 + CD25 T conventional (Tconv) cells from C56BL/6 mice were labeled with carboxyfluorescein succinimidyl ester (CFSE) and co-stimulated with irradiated antigen presenting cells (irradiated CD09.2 APC) plus CD3e mAb (1 pg /mL, BD PharMingen).
- Treg (CD4 + CD25 + ) cells were added at the indicated ratios to suppress Tconv proliferation. After 72 hours, proliferation of Tconv cells was determined by flow cytometric analysis of CFSE or CellTrace dilution. The number in the flow plots shows the percent Tconv cells that underwent one or more cellular division. Decreased effector T (Teff) cells proliferation was observed with higher doses of kynurenine.
- Figures 2A and 2B provide analysis on Kynurenine metabolites.
- CD4 + CD25 Tconv cells were stimulated with irradiated antigen presenting cells and with CD3/CD28 mAb beads for 16 hours and exposed to 1 mM L- or D-kynurenine for 3 hours.
- [ 13 C 6 ] glucose at 60 mg/dL was used for a 3-hour labeling.
- Metabolites were extracted and analyzed by LC-MS. Relative total ion counts of Kynurenine are plotted in Figure 2A while relative total ion counts of Kynurenic acid are shown in Figure 2B.
- Figure 3A shows that Foxp3+ Induced Treg (iTreg, CD4 + CD25 + Foxp3 + ) formation is not augmented with kynurenine (decreased with toxicity).
- Purified CD4 + CD25 T conventional (Tconv) cells from C56BL/6 mice were labeled with CFSE and co-stimulated with irradiated antigen presenting cells (irradiated CD09.2 APC) plus CD3e mAb (1 pg /mL, BD PharMingen). CD4 + lymphocytes were gated.
- D-Kynurenine, L-Kynurenine or Ro6l-8048 (a Kynurenine 3- monooxygenase (KMO or kynurenine hydroxylase) inhibitor) were incubated with the cells at concentrations indicated in the figure.
- Figures 3B and 3C show that Kynurenine-induced apoptosis.
- Purified CD4 + CD25 T conventional (Tconv) cells from C56BL/6 mice were labeled with CFSE and co-stimulated with irradiated antigen presenting cells (irradiated CD09.2 APC) plus CD3e mAb (1 pg /mL, BD PharMingen) for 3 days.
- FIG. 4A shows that incubation of human T cells with 1 mM Kynurenine inhibits T cell proliferation and induces apoptosis.
- human CD4+ T cells from healthy donor were stimulated with anti-CD3e/CD28 mAb coated beads for 4 days and labeled with CFSE. Additional staining was performed in order to differentiate live cells from dead cells. CD4 + cells were gated. Kynurenine-induced cell death is observed in human T cells, consistent with previous findings in murine T cells.
- Figures 5A and 5B show effects of Kynurenines on IFN-g production.
- CD8 + T cells from C56BL/6 mice were acquired and stimulated via culture on anti-CD3e/CD28 mAb coated plates overnight and incubated with PMA/ionomycin for five hours. IFN-g production was evaluated. Representative flow cytometry plots can be found in Figure 5A while Figure 5B provides a bar graph summarizing relative IFN-g production upon treatment with 250 mM, 500 mM, 1 mM, or 2 mM of L- or D-Kynurenine.
- Figure 6 shows the effects of Kynurenines on IFN-g production and cell viability.
- CD8 + T cells from C56BL/6 mice were acquired and stimulated by culture on anti-CD3e/CD28 mAb coated plates overnight and incubated with PMA/ionomycin for five hours. Staining was performed to distinguish live cells v.s. dead cells.
- Figure 7 shows fatty acid depletion by treatment with L- or D-kynurenine.
- CD4 + CD25 Tconv cells were stimulated by contact with CD3/CD28 mAb beads for 16 hours and exposed to L- or D-kynurenine for 3 hours.
- glucose at 60 mg/dL was used for a 3-hour labeling.
- Metabolites were extracted and analyzed. Total ion counts showed a reduction of lipids after 3 hours (10% FBS, RPMI 1640). The results support that Kynurenines induce lipid catabolism.
- Figure 8A provides rescue of T cell phenotype with adding Oleate or Palmitate.
- CD4 + CD25 Tconv cells were co-stimulated and exposed to 1 mM L- or D-kynurenine for 3 hours.
- glucose at 60 mg/dL was used for a 3-hour labeling.
- Kynurenine ablated T cell proliferation (apoptosis).
- FIGS 8B and 8C show that effects of T cell apoptosis are highly dependent upon experimental conditions, including addition of bovine serum albumin (BSA) or number of cells treated per well.
- BSA bovine serum albumin
- Human T cells were co-stimulated with CD3e/CD28 monoclonal antibodies (mAb) with lOOk cells per well or 200k cells per well, with or without BSA or 0.2 mM Oleate/Palmitate.
- Figures 9A to 9E provide in vivo results of Kynurenine treatments.
- B6/Ragl 7 mice (with all the same age and gender, i.e., 16+6 week, female)) were injected with Tconv 36 .
- Figure 9C provides percentages of Foxp3 + cells (Treg cells) out of CD4+ cells upon treatment with D- or L- kynurenine. No difference in induced Foxp3+ cells, suggesting no augmentation of Treg upon treatment.
- Figures 9D and 9E show Kynurenine slowed weight gain. Weight was normalized to starting weight (day of Tconv injection).
- the present invention is based on the observation that different isomers of kynurenine drive this pathway in one direction of another. The present inventor has discovered that immunosuppression can be reduced or enhanced depending on which isomer of kynurenine is used to contact T cells.
- a key difference in D- kynurenine over L-kynurenine is that a key enzyme in L-kynurenine degradation, kynureninase, is specific to the L-kynurenine isomer and cannot metabolize the D-isomer to anthranilic acid. 44, 45 , 21, 22 D_Kynurenine can therefore not contribute to quinolinic acid production, avoiding the excitotoxicity that high dose (>300 mg/kg/d) L-kynurenine metabolism can cause in the brain. Kynurenic acid even has neuroprotective properties 46 .
- Kynureninase inhibition is a neuroprotective treatment strategy to shunt kynurenine metabolites away from quinolinic acid to kynurenic acid. 47,48 In addition, this also avoids mixed or pro-inflammatory metabolites downstream of L-, but not D-kynurenine, and re-route kynurenine metabolites to aryl hydrocarbon receptor (AHR) agonists.
- AHR agonists have been suggested to be a key mediator of Foxp3 + regulatory T cell induction and suppressive function. 23, 24, 49 Accordingly, the methods of the present invention may be used in the treatment of an autoimmune disease or other diseases/disorders/conditions where suppression of the immune response is desired.
- Autoimmune diseases that may be treated by the methods of the present invention include, but are not limited to, acute disseminated encephalomyelitis (ADEM), Addison's disease, ankylosing spondylitisis, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hepatitis, autoimmune uveitis celiac disease, Crohn's disease, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, idiopathic thrombocytopenic purpura, insulin dependent diabetes mellitus (IDDM) lupus erythematosus, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, opsoclonus myoclonus syndrome (OMS), Ord's thyroiditis, pemphigus, pernicious Anaemia, polyarthritis, primary biliary cirrhosis, rheuma
- the methods of the invention can also be used to advantage for the inhibition of allograft rejection and/or in the treatment of graft versus host disorders, for example, after bone marrow transplantation, after a kidney transplantation, after a liver transplantation, or after a cardiac transplantation.
- use of a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan as described herein, optionally, in conjunction with an immunosuppressant other than the product or an analog thereof may prevent, delay, slow the progression of, alleviate, or cure an allograft rejection.
- diseases or disorders or conditions where suppression of the immune response is desired may include, for example, allergic disease, nephrotic syndrome requiring
- Such drug may be a protein, a peptide, an antibody, or a gene therapy vector.
- the described methods, uses, and compositions may delay the appearance of a symptom associated with the diseases/disorders/conditions, slow the progression of the
- diseases/disorders/conditions alleviate or cure the diseases/disorders/conditions.
- use of a metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of D-tryptophan as described herein, in conjunction with an immunosuppressant other than the product or an analog thereof may reduce dose and/or administration frequency of the immunosuppressant, resulting in an alleviated toxicity effects of the immunosuppressant.
- alleviation of a toxicity effect refers to no or delayed appearance of the toxicity effect, and/or a toxicity effect at a less severe level or a lower frequency.
- Such toxicity effects include, for example, one or more of the following: weight gain: hypertension; hyperglycemia, diabetogenic effects; renal toxicity; diarrhea, constipation, nausea or vomiting: heartburn: stomach pain: loss of appetite: headache: uncontrollable shaking of a part of the body: difficulty falling asleep or staying asleep: dizziness: weakness: joint or back pain: rash or itching: burning, pain, numbness, or tingling in the hands or feet; decreased, painful, and/or burning urination; swelling of the hands, arms, feet, ankles, or lower legs; unusual bruising or bleeding; seizures; coma; blurred vision, eye pain, or seeing halos around lights; swelling, rapid weight gain, feeling short of breath; severe depression, feelings of extreme happiness or sadness, changes in personality or behavior, seizure (convulsions); bloody or tarry stools, coughing up blood; pancreatitis (severe pain in upper stomach spreading to back, nausea and vomiting, fast heart rate); low potassium (confusion, uneven heart rate
- an“effective amount” of a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of D-tryptophan as provided herein is the amount which achieves desired amelioration of diseases or conditions as described herein and/or alleviation of a toxicity effect of an immunosuppressant.
- an “effective amount” of a metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of tryptophan as provided herein is the amount which achieves one or more of the following endpoints: a delay in appearance of a symptom associated with a disease/disorder/condition as described herein, a slower progression of a disease/disorder/condition as described herein, an alleviated symptom or no symptom associated with a disease/disorder/condition as described herein, prevention of a disease/disorder/condition (for example, allograft rejection), and alleviation of a toxicity effect associated with an immunosuppressant which includes no or delayed appearance of a toxicity effect, and/or a toxicity effect at a less severe level or a lower frequency.
- IDO indolamine dioxygenase
- IDO-l indoleamine 2,3- dioxygenase, EC 1.13.11.52
- IDO-2 indoleamine-pyrrole 2,3 dioxygenase-like 1, EC 1.13.11.-
- TDO tryptophan 2,3-dioxygenase, EC 1.13.11.11
- IDO-l can also catabolize serotonin and melatonin although the substrate specificity for IDO-2 and TDO is not so well studied.
- Metabolites or catabolites from the tryptophan pathway are Tryptophan, N-Formyl-kynurenine, Formylanthranilate,
- Tregs are potent suppressors of T cell mediated immunity in a range of inflammatory conditions, including infectious disease, autoimmunity, pregnancy and tumors (Sakaguchi, S, Nat Immunol 2005; 6:345-352). Mice lacking Tregs die rapidly of uncontrolled autoimmune disorders (Khattri et al. Nat Immunol 2003; 4:337-342). In vivo, a small percentage of Tregs can control large numbers of activated effector T cells. Although freshly isolated Tregs exhibit minimal constitutive suppressor functions, ligating the T cell antigen receptor (TCR) in vitro (Thornton et al.
- TCR T cell antigen receptor
- alloantigen is defined herein as an antigen present only in an allograft from a allograft donor and capable of inducing the production of an alloantibody response by allograft recipients
- immunoprotective is defined herein as an effect which reduces, arrests, or ameliorates immunological insult and is protective, resuscitative or revivative for affected tissue that has suffered cytotoxic insult from immune cells or inflammation.
- immunoprotective agent is herein defined as active ingredient or medicament containing an immune insult treatment dose of active ingredient effective in reducing, preventing, arresting, or ameliorating immune insult and provides protection, resuscitation or revival to affected tissue that has suffered immune mediated insult.
- buffer is intended to mean an aqueous solution containing an acid-base mixture with the purpose of stabilising pH.
- buffers are Trizma, Bicine, Tricine, MOPS, MOPSO, MOBS, Tris, Hepes, HEPBS, MES, phosphate, carbonate, acetate, citrate, glycolate, lactate, borate, ACES, ADA, tartrate, AMP, AMPD, AMPSO, BES, CABS, cacodylate, CHES, DIPSO, EPPS, ethanolamine, glycine, HEPPSO, imidazole, imidazolelactic acid, PIPES, SSC, SSPE, POPSO, TAPS, TABS, TAPSO and TES.
- diluent is intended to mean an aqueous or non-aqueous solution with the purpose of diluting the medicament.
- the diluent may be one or more of saline, water, polyethylene glycol, propylene glycol, ethanol or oils (such as safflower oil, com oil, peanut oil, cottonseed oil or sesame oil).
- An excipient may be one or more of carbohydrates, polymers, lipids and minerals.
- carbohydrates include lactose, sucrose, mannitol, and cyclodextrines, which are added to the composition, e.g., for facilitating lyophilisation.
- polymers are starch, cellulose ethers, cellulose carboxymethylcellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose, alginates, carageenans, hyaluronic acid and derivatives thereof, polyacrylic acid, polysulphonate, polyethylenglycol/polyethylene oxide, polyethyleneoxide/polypropylene oxide copolymers, poly vinylalcohol/poly vinylacetate of different degree of hydrolysis, and polyvinylpyrrolidone, all of different molecular weight, which are added to the composition, e.g., for viscosity control, for achieving bioadhesion, or for protecting the lipid from chemical and proteolytic degradation.
- lipids are fatty acids, phospholipids, mono-, di-, and triglycerides, ceramides, sphingolipids and glycolipids, all of different acyl chain length and saturation, egg lecithin, soy lecithin, hydrogenated egg and soy lecithin, which are added to the composition for reasons similar to those for polymers.
- minerals are talc, magnesium oxide, zinc oxide and titanium oxide, which are added to the composition to obtain benefits such as reduction of liquid accumulation or advantageous pigment properties.
- compositions of the invention may be administrated by any suitable route including oral, sublingual, buccal, nasal, inhalation, parenteral (including intraperitoneal, intraorgan, subcutaneous, intradermal, intramuscular, intra- articular, venous (central, hepatic or peripheral), lymphatic, cardiac, and arterial, with parenteral being the preferred route.
- parenteral including intraperitoneal, intraorgan, subcutaneous, intradermal, intramuscular, intra- articular, venous (central, hepatic or peripheral), lymphatic, cardiac, and arterial, with parenteral being the preferred route.
- the preferred route may vary depending on the condition of the patient.
- the terms“reduce”“decrease”“alleviate”“ameliorate”“improve” “delay”“earlier”“lower”“mitigate”, any grammatical variation thereof, or any similar terms indication a change means a variation of about 5 fold, about 2 fold, about 1 fold, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5 % compared to a reference (e.g., a healthy control, a subject having a disease/disorder/condition as described herein, a subject having transplantation, a subject having an autoimmune disease, a subject having a graft versus host disease, an standard immunosuppressant regimen achieving similar or the same immune suppression effect without using the described metabolic breakdown product of tryptophan or an analog thereof), unless otherwise specified.
- a reference e.g., a healthy control, a subject having a disease/disorder/condition as described herein, a subject having transplantation,
- an immunosuppressant is administered to a subject 0, 1, 2, 3, 4,
- immunosuppressant administration may involve administration of one, two or more immunosuppressants (e.g., glucocorticoids, prednelisone, micophenolate mofetil (MMF) and/or sirolimus (i.e., rapamycin)). Additionally, or alternatively, such immunosuppressant(s) may be administrated to a subject in need once, twice or for more times at the same dose or an adjusted dose.
- immunosuppressants e.g., glucocorticoids, prednelisone, micophenolate mofetil (MMF) and/or sirolimus (i.e., rapamycin).
- MMF micophenolate mofetil
- sirolimus i.e., rapamycin
- Immunosuppressants for such co-therapy include, but are not limited to, tacrolimus, prednisone, a glucocorticoid, steroids, antimetabolites, T-cell inhibitors, a macrolide (e.g ., a rapamycin or rapalog), and cytostatic agents including an alkylating agent, an anti-metabolite, a cytotoxic antibiotic, an antibody, or an agent active on immunophilin.
- the immune suppressant may include a nitrogen mustard, nitrosourea, platinum compound, methotrexate, azathioprine, mercaptopurine, fluorouracil, dactinomycin, an anthracy cline, mitomycin C, bleomycin, mithramycin, IL-2 receptor- (CD25-) or CD3 -directed antibodies, anti-IL-2 antibodies, cyclosporin, tacrolimus, sirolimus, IFN-b, IFN-g, an opioid, or TNF-a (tumor necrosis factor-alpha) binding agent.
- IDO Indoleamine 2,3 -dioxygenase
- IDO an enzyme involved in the catabolism of tryptophan
- IDO prevents rejection of the fetus during pregnancy probably by inhibiting alloreactive T cells, and it was suggested that IDO- expression in antigen-presenting cells may control autoreactive immune responses.
- kynurenine is an IDO degradation product.
- Kynurenine can be in an L- or D- isomer form.
- a key difference in D-kynurenine over L- kynurenine is that a key enzyme in L-kynurenine degradation, Kynureninase, is specific to the L- kynurenine isomer and cannot metabolize the D-isomer. 21, 22
- This feature could be exploited for developing agent which avoid mixed or pro-inflammatory metabolites downstream of L-, but not D-kynurenine, thereby re-routing kynurenine metabolites to aryl hydrocarbon receptor (AHR) agonists.
- AHR agonists have been suggested to be a key mediator of Foxp3 + regulatory T cell induction and suppressive function.
- LC-MS and [ 13 C 6 ] glucose tracing studies are performed in order to reveal depletion of post-GAPDH glycolytic intermediates with or without L-, D- or mixed isoforms of kynurenine.
- Tconv were co-stimulated and cultured in low glucose medium (30 mg/dL) for 48 hours with or without L-, D- or mixed isoforms of kynurenine, and 1 mM heptelidic acid (GAPDHi) or DMSO vehicle control.
- GPDHi heptelidic acid
- Tconv and CTL are co-stimulated and cultured with or without L-, D- or mixed isoforms of kynurenine.
- Tconv are also stimulated with CD3e/CD28 for 16 hours and then labeled with 60 mg/dL [ 13 C 6 ] D-glucose or [ 13 C 3 ] Pyruvate for 2 hr with or without L-, D- or mixed isoforms of kynurenine.
- Metabolites are extracted and analyzed via LC-MS, resulting a heatmap showing increased and decreased glycolytic inter-mediates ion count normalized to control.
- Glucose derivatives are investigated through [ 13 C 6 ] D-glucose.
- the effect of kynurenine on glucose, glutamine and fatty acid metabolism is characterized through heavy carbon [ 13 C] metabolic flux tracer studies.
- Also assessed are the direction of the Krebs cycle (reductive/oxidative), redox- dependent rerouting of metabolic pathways and effects on the production of immune regulatory metabolites.
- Glycolytic intermediates can be re-routed to e.g. the pentose phosphate pathway 55 , one carbon metabolism 56 , or the methylglyoxal pathway 57 60 .
- Such altered pathways can be functionally important to T cell function 61 .
- the amount of heavy carbon isotopes in citrate is tracked, indicating how citrate was formed out of [ 13 Cs] L-glutamine (M+5 reductive vs. M+4 oxidative). Also tracked are other glutamine derived metabolites such as 2-HG.
- autoimmune colitis is induced by chronic administration of dextran sulfate sodium to C57BL/6 mice and adoptive transfer of CD4 + Tconv isolated from wildtype (WT) C57BL/6 mice into
- kidney transplant model BALB/c kidneys are transplanted to nephrectomized C57BL/6 recipients who depend on allograft function to survive. 29 A second BALB/c to
- C57BL/6 cardiac allograft model is also used to determine if the dose of tacrolimus (an immunosuppressant) required to maintain an allograft can be lowered with kynurenine (D- or L- or mixed isoform) treatment.
- tacrolimus an immunosuppressant
- kynurenine D- or L- or mixed isoform
- kidney transplant model allows investigating long-term differences between the D-/L- kynurenine-treated vs. the control groups than the cardiac transplant model 16 .
- mice are used for these in vivo studies. 5-10 or 10-15 mice are used per group of both female and male mice. Statistical analysis (normal distribution testing, comparative statistics) assesses significance.
- Na kynurenine in D- or L- or mixed isoform is provided through the drinking water, food, and/or intraperitoneal ⁇ i.p.) injections.
- Kynurenine in D- or L- or mixed isoform is administered through i.p. injections (30 mg/kg/d), or enteral administration via diet (300 mg/kg/d, more details about this administration can be found in reference 30).
- NaCl (vs. no additive) is used as a negative control. Animal survival, allograft function and metabolites are monitored, while graft histology and intragraft lymphocytes are evaluated to assess mechanisms linked with graft rejection or survival. For example, median allograft survival is calculated;
- C57BL/6 mice are transplanted with BALB/c kidneys.
- the native kidneys are removed after 7 days.
- removal of the native kidneys makes the mice dependent on renal allograft function to survive.
- 70 pL of blood (Chem8, Abbott) which is obtained weekly. This quantity of blood removal is well tolerated and does not affect hematologic parameters 28,50 .
- Kynurenine treatment induced donor specific tolerance is evaluated.
- Mice developing longer than 100 days’ allograft survival receive a cervical 3rd party (C3H, H-2k) or a BALB/C (H-2d re-exposure) cardiac allograft to the neck 28 .
- Neck cardiac allograft survival are tracked by palpation, histology and immunohistochemistry 28 .
- Kynurenine can allow to lower the dose of conventional immunosuppressive therapy (i.e . tacrolimus).
- C57BL/6 mice are transplanted with B ALB/c abdominal cardiac allografts 16, 51, 52 .
- the recipients were treated with a subtherapeutic dose of tacrolimus (1 mg/kg/d), on which the mice would be expected to reject 53 .
- 1 mg/kg of tacrolimus administered to C57BL/6 mice had barely any effect on T cell function 54 .
- Kynurenine administration is performed as indicated above and tested if it can prolong cardiac allograft survival.
- Body NAD:NADH ratios are further investigated via collecting liver, spleen, colon, and allograft tissue in liquid nitrogen, and later measuring NAD:NADH 16 as well as histone acetylation/methylation.
- transplant-induced weight gain and diabetes are studied in these two models. Detailed methods can be found in the following Example.
- mice 6-week-old female Ragl _/_ mice were injected i.p. with 1 x 10 6 of B6 Tconv cells on Day 0. Starting on Day 7, D-Kynurenine, L-Kynurenine or control was administered i.p. at a dose of 30 mg/kg/day on Days 7-11, 14-18 and 21-24. Body weight was measured on days 0, 8, 16, 18, 23 and 25. On Day 25, mice were sacrificed. Serum and other tissues were harvested for further analysis. Immunosuppressive response in vivo is also evaluated. We observed that Kynurenine treatment slowed weight gain, suggesting that Kynurenine may affect immunosuppressant associated weight gain. See, Figures 9D and 9E.
- an established model of assessing prednisone induced weight gain and hyperglycemia 31 is used with modifications to control for the effects of gender and microbiota 32 .
- Home-bred C57BL/6 are used.
- Regular chow diet providing 25% kcal from fat is provided to mice after weaning.
- Four weeks after weaning i.e., about 9 weeks to 12 weeks of age, all mice (both genders) are exposed to a high fat diet (45% kcal from fat) with high dose
- methylprednisolone (10 mg/kg/g i.p.) injections, with either Na D-Kynurenine i.p. injections (30 mg/kg/d) or vehicle control.
- Body weight is tracked. Serum glucose and insulin are measured weekly. A glucose tolerance test is performed at week 12, after which serum and tissue are collected. Results relating to weight, hyperglycemia, or insulin resistance phenotype are analyzed to evaluate the alleviation of D-kynurenine treatment. T cell metabolism, caloric intake and energy expenditure are also explored.
- enteral formulations which could achieve even higher doses are investigated using the same experimental setting.
- kynurenine L-, D- or mixed isoform
- the metabolic effect of kynurenine on glucose, glutamine and fatty acid metabolism is characterized through heavy carbon [ 13 C] metabolic flux tracer studies. Also assessed are the direction of the Krebs cycle (reductive/oxidative), redox-dependent rerouting of metabolic pathways and effects on the production of immune regulatory metabolites.
- Metabolic pathways affected by kynurenine are identified, which can include T cell glycolysis (cytokine production, 13, 33 or intracellular calcium 15 ), de novo lipogenesis of Thl7 T cells indicating that targeting acetyl-CoA carboxylase 1 shifts Thl7 formation towards Foxp3+ Treg 35 , the reverse Krebs cycle which is important to highly proliferating cells under hypoxic conditions 36 affecting malate dehydrogenase activity and favoring a-ketoglutarate metabolism to L-2-HG and subsequent effects on DNA methylation 37 , the metabolic sequelae of conventional immunosuppression such as tacrolimus and prednisone (weight gain, diabetogenic) 38 , and more 34 .
- kynurenine treatment may alleviate some of these problems by dose reduction of conventional immunosuppressants, and maybe by counteracting certain co-morbid pathologies, such as weight gain.
- T cells are labeled using heavy carbon tracers [ 13 C 6 ] D-glucose, [ 13 Cs] L-glutamine, and [ 13 C1 ⁇ 2] palmitate each in separate experiments (all in biological triplicate at minimum). After labeling, metabolites are methanol-extracted and submitted for LC/MS derivative analysis. Methods were detailed 16, 39 4(443 .
- PMC5898814 40 Liu, L., X. Su, W.J. Quinn, 3rd, S. Hui, K. Krukenberg, D.W. Frederick, P. Redpath, L. Zhan, K. Chellappa, E. White, M. Migaud, T.J. Mitchison, J.A. Baur and J.D.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Rehabilitation Therapy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods for modulating immunosuppression are disclosed. This invention relates the fields of T cell regulation and therapeutic immunosuppression. More specifically, the invention provides compositions and methods for selective immunosuppressive therapies for the treatment of autoimmune diseases and allograft recipients.
Description
Compositions and Methods for Modulating Immunosuppression
This invention was made with government support under grant number K08 AI095353 01 awarded by The National Institutes of Health. The US government has certain rights in the invention.
Cross-Reference to Related Applications
This application claims priority to US Provisional Patent Application No: 62/731,660 filed
September 14, 2018, the entire contents being incorporated herein by reference as thought set forth in full. Field of the Invention
This invention relates the fields of T cell regulation and therapeutic immunosuppression. More specifically, the invention provides compositions and methods for selective
immunosuppressive therapies for the treatment of autoimmune diseases and allograft recipients .
Background of the Invention Several publications and patent documents are cited through the specification in order to describe the state of the art to which this invention pertains. Each of these citations is incorporated herein by reference as though set forth in full.
Therapeutic immunosuppression is required for many medical conditions ranging from autoimmune diseases to transplantation.1 6 Unfortunately, current immunosuppressive medications are limited by non- specificity and toxicities,7, 8 and more precise and safer drugs are needed. For example, organ transplantation is potentially curative for patients suffering from organ failure; however, transplanted allografts require ongoing immunosuppression to prevent rejection. Current immunosuppressive medications are fairly effective at preventing acute allograft rejection, but are often associated with substantial toxicity. Prednisone induces weight gain, hypertension, and hyperglycemia, while tacrolimus causes renal toxicity, hypertension, and can induce diabetes, to name but a few complications associated with current therapies. These
common problems are frequently seen in most transplant programs, and among other patients requiring immunosuppressive therapy, across the United States and worldwide.
There are many examples in mammalian biology of how local environments foster immune regulation through alterations in cell metabolism, such as in the gastrointestinal tract, during pregnancy, and, unfortunately, in the tumor microenvironment (TME). The TME surrounding solid cancers is particularly effective at promoting immune evasion and resistance to anti-tumor therapies. TME metabolism, as well as immune privileged tissues, is characterized by low glucose, glutamine and tryptophan, while lactic acid and kynurenines are enriched, all of which weaken anti-tumor immunity.9 1 1 Cytotoxic and effector T cells (CTL, Teff) require glycolysis to proliferate and produce cytokines, and become ineffective in the TME.12 15 We observed, that in contrast to Teff and CTL, regulatory T cells (Treg) are very well adapted to low-glucose, high lactate TME metabolism.16 Hence, the TME suppresses selective effector responses while suppressive and regulatory elements are favored.17
Current immunosuppressive therapies are limited by toxicities and a lack of specificities. Clearly, a need exists for improved therapies for the selective and effective immunosuppression in patients in need thereof.
Summary of the Invention
The present invention provides a method of modulating immune suppression mediated by T cells (for example, by mediating proliferation or viability or apoptosis or cell death of T cells, or conventional T cells, or mature T cells, or cytotoxic T cells, or effector T cells, or regulatory T cells) in a subject, the method including administering to the subject a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of D-tryptophan, in an amount effective to suppress undesirable immune responses. In preferred embodiments, the product is D-kynurneine. D-kynurneine is preferred over L-kynumeine as D-kynurneine does not exhibit the brain toxicity observed when L-kynumeine is administered.
In one embodiment, the invention provides a method for the treatment of autoimmune disease in a subject in need thereof, the method including administering to the subject a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan, and optionally, one or more alloantigens present in the allograft, wherein said product is D-kynurneine.
The present invention also includes a method of preventing allograft rejection in a subject, the method including administering to the subject a metabolic breakdown product of D- tryptophan, or an analog of a metabolic breakdown product of D-tryptophan, and optionally, one or more alloantigens present in the allograft, wherein said product is D-kynurneine.
The present invention also includes a method of preventing graft versus host disease in a recipient, the method including administering to the donor a metabolic breakdown product of D- tryptophan, or an analog of a metabolic breakdown product of D-tryptophan, and one or more alloantigens present in the recipient, wherein the metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of D-tryptophan, and the one or more
alloantigens present in the recipient are administered to the donor prior to obtaining donor cells from the donor; obtaining donor cells from the donor; and administering the donor cells to the recipient.
Also provide are compositions comprising at least one metabolic breakdown product of D-tryptophan, and/or an analog of a metabolic breakdown product of tryptophan, for use in the methods and uses described. In one embodiment, the product is D-kynurneine. In one
embodiment, the composition further comprises an immunosuppressant which is not a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan.
In a preferred embodiment, the methods and compositions disclosed herein may be used along with an immunosuppressant other than the metabolic breakdown product of tryptophan or an analog a metabolic breakdown product of tryptophan. In one embodiment, the metabolic breakdown product is D-kynurneine. In certain embodiments, the metabolic breakdown product of tryptophan or an analog thereof reduces dose of the immunosuppressant and/or administration frequency of the immunosuppressant for the subject compared to a regimen utilizing the immunosuppressant only without the metabolic breakdown product of tryptophan or an analog thereof. In a further embodiment, the metabolic breakdown product of tryptophan or an analog thereof alleviates/mitigates toxicity of the immunosuppressant. In certain embodiments, the metabolic breakdown product of tryptophan or an analog thereof improves specificity of the immunosuppressant while preserving the subject’s ability to fight infections and cancer.
Brief Description of the Drawing
Figure 1 provides results of a Kynurenine regulatory T (Treg) cells suppression assay. Purified CD4+CD25 T conventional (Tconv) cells from C56BL/6 mice were labeled with carboxyfluorescein succinimidyl ester (CFSE) and co-stimulated with irradiated antigen presenting cells (irradiated CD09.2 APC) plus CD3e mAb (1 pg /mL, BD PharMingen). Treg (CD4+CD25+) cells were added at the indicated ratios to suppress Tconv proliferation. After 72 hours, proliferation of Tconv cells was determined by flow cytometric analysis of CFSE or CellTrace dilution. The number in the flow plots shows the percent Tconv cells that underwent one or more cellular division. Decreased effector T (Teff) cells proliferation was observed with higher doses of kynurenine.
Figures 2A and 2B provide analysis on Kynurenine metabolites. CD4+CD25 Tconv cells were stimulated with irradiated antigen presenting cells and with CD3/CD28 mAb beads for 16 hours and exposed to 1 mM L- or D-kynurenine for 3 hours. [13C6] glucose at 60 mg/dL was used for a 3-hour labeling. Metabolites were extracted and analyzed by LC-MS. Relative total ion counts of Kynurenine are plotted in Figure 2A while relative total ion counts of Kynurenic acid are shown in Figure 2B.
Figure 3A shows that Foxp3+ Induced Treg (iTreg, CD4+ CD25+ Foxp3+) formation is not augmented with kynurenine (decreased with toxicity). Purified CD4+CD25 T conventional (Tconv) cells from C56BL/6 mice were labeled with CFSE and co-stimulated with irradiated antigen presenting cells (irradiated CD09.2 APC) plus CD3e mAb (1 pg /mL, BD PharMingen). CD4+ lymphocytes were gated. D-Kynurenine, L-Kynurenine or Ro6l-8048 (a Kynurenine 3- monooxygenase (KMO or kynurenine hydroxylase) inhibitor) were incubated with the cells at concentrations indicated in the figure. Figures 3B and 3C show that Kynurenine-induced apoptosis. Purified CD4+CD25 T conventional (Tconv) cells from C56BL/6 mice were labeled with CFSE and co-stimulated with irradiated antigen presenting cells (irradiated CD09.2 APC) plus CD3e mAb (1 pg /mL, BD PharMingen) for 3 days. Staining was performed to distinguish live cells from dead cells, for example using Live/Dead Aqua, an amine reactive dye which binds covalently to amines. Summary of 5 murine Treg suppression assays were plotted as a bar graph shown in Figure 3C. Kynurenine-induced cell death is observed in murine T cells, as has been previously observed.
Figure 4A shows that incubation of human T cells with 1 mM Kynurenine inhibits T cell proliferation and induces apoptosis. As shown in Figure 4A, human CD4+ T cells from healthy donor were stimulated with anti-CD3e/CD28 mAb coated beads for 4 days and labeled with CFSE. Additional staining was performed in order to differentiate live cells from dead cells. CD4+ cells were gated. Kynurenine-induced cell death is observed in human T cells, consistent with previous findings in murine T cells.
Figures 5A and 5B show effects of Kynurenines on IFN-g production. CD8+ T cells from C56BL/6 mice were acquired and stimulated via culture on anti-CD3e/CD28 mAb coated plates overnight and incubated with PMA/ionomycin for five hours. IFN-g production was evaluated. Representative flow cytometry plots can be found in Figure 5A while Figure 5B provides a bar graph summarizing relative IFN-g production upon treatment with 250 mM, 500 mM, 1 mM, or 2 mM of L- or D-Kynurenine.
Figure 6 shows the effects of Kynurenines on IFN-g production and cell viability. CD8+ T cells from C56BL/6 mice were acquired and stimulated by culture on anti-CD3e/CD28 mAb coated plates overnight and incubated with PMA/ionomycin for five hours. Staining was performed to distinguish live cells v.s. dead cells.
Figure 7 shows fatty acid depletion by treatment with L- or D-kynurenine. CD4+CD25 Tconv cells were stimulated by contact with CD3/CD28 mAb beads for 16 hours and exposed to L- or D-kynurenine for 3 hours. [13C6] glucose at 60 mg/dL was used for a 3-hour labeling. Metabolites were extracted and analyzed. Total ion counts showed a reduction of lipids after 3 hours (10% FBS, RPMI 1640). The results support that Kynurenines induce lipid catabolism.
Figure 8A provides rescue of T cell phenotype with adding Oleate or Palmitate.
CD4+CD25 Tconv cells were co-stimulated and exposed to 1 mM L- or D-kynurenine for 3 hours. [13C6] glucose at 60 mg/dL was used for a 3-hour labeling. Consistent with the results shown in Figure 8, Kynurenine ablated T cell proliferation (apoptosis). Addition of
Oleate/Palmitate rescued the phenotype and restored T cell proliferation. Figures 8B and 8C show that effects of T cell apoptosis are highly dependent upon experimental conditions, including addition of bovine serum albumin (BSA) or number of cells treated per well. Human T cells were co-stimulated with CD3e/CD28 monoclonal antibodies (mAb) with lOOk cells per well or 200k cells per well, with or without BSA or 0.2 mM Oleate/Palmitate.
Figures 9A to 9E provide in vivo results of Kynurenine treatments. B6/Ragl 7 mice (with all the same age and gender, i.e., 16+6 week, female)) were injected with Tconv36. After 1 week, the mice were treated with 30 mg/kg D- or L-kynurenine 5/7 days/week i.p. for 3 weeks. Figures 9A to 9B show that Kynurenines suppress T cell function in vivo, indicating Kynurenine treated mice showed less homeostatic proliferation than NaCl control (n=5, one-way ANOVA). Figure 9C provides percentages of Foxp3+ cells (Treg cells) out of CD4+ cells upon treatment with D- or L- kynurenine. No difference in induced Foxp3+ cells, suggesting no augmentation of Treg upon treatment. Figures 9D and 9E show Kynurenine slowed weight gain. Weight was normalized to starting weight (day of Tconv injection). Kynurenine treated mice showed less weight gain (L-Kyn, p<0.05) or a trend to less weight gain (D-Kyn) compared to NaCl control (n=5, AUC). Observable effects were found on T cell proliferation in vivo, without overt toxicity.
Detailed Description of the Invention
Depletion of tryptophan and an increase of its metabolites from the kynurenine pathway have been recognized as mechanisms of immunosuppression though the induction of T cell apoptosis and the strengthening of regulatory T cells.18 20 The present invention is based on the observation that different isomers of kynurenine drive this pathway in one direction of another. The present inventor has discovered that immunosuppression can be reduced or enhanced depending on which isomer of kynurenine is used to contact T cells. A key difference in D- kynurenine over L-kynurenine is that a key enzyme in L-kynurenine degradation, kynureninase, is specific to the L-kynurenine isomer and cannot metabolize the D-isomer to anthranilic acid.44, 45,21, 22 D_Kynurenine can therefore not contribute to quinolinic acid production, avoiding the excitotoxicity that high dose (>300 mg/kg/d) L-kynurenine metabolism can cause in the brain. Kynurenic acid even has neuroprotective properties46. In fact, in Neurobiology, Kynureninase inhibition is a neuroprotective treatment strategy to shunt kynurenine metabolites away from quinolinic acid to kynurenic acid.47,48 In addition, this also avoids mixed or pro-inflammatory metabolites downstream of L-, but not D-kynurenine, and re-route kynurenine metabolites to aryl hydrocarbon receptor (AHR) agonists. AHR agonists have been suggested to be a key mediator of Foxp3+ regulatory T cell induction and suppressive function.23, 24, 49
Accordingly, the methods of the present invention may be used in the treatment of an autoimmune disease or other diseases/disorders/conditions where suppression of the immune response is desired.
Autoimmune diseases that may be treated by the methods of the present invention include, but are not limited to, acute disseminated encephalomyelitis (ADEM), Addison's disease, ankylosing spondylitisis, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hepatitis, autoimmune uveitis celiac disease, Crohn's disease, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, idiopathic thrombocytopenic purpura, insulin dependent diabetes mellitus (IDDM) lupus erythematosus, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, opsoclonus myoclonus syndrome (OMS), Ord's thyroiditis, pemphigus, pernicious Anaemia, polyarthritis, primary biliary cirrhosis, rheumatoid arthritis, Reiter's syndrome, Sjogren's syndrome, Takayasu's arteritis, temporal arteritis (also known as giant cell arteritis), warm autoimmune hemolytic anemia, and Wegener's granulomatosis.
The methods of the invention can also be used to advantage for the inhibition of allograft rejection and/or in the treatment of graft versus host disorders, for example, after bone marrow transplantation, after a kidney transplantation, after a liver transplantation, or after a cardiac transplantation. In certain embodiments, use of a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan as described herein, optionally, in conjunction with an immunosuppressant other than the product or an analog thereof may prevent, delay, slow the progression of, alleviate, or cure an allograft rejection.
Other diseases or disorders or conditions, where suppression of the immune response is desired may include, for example, allergic disease, nephrotic syndrome requiring
immunosuppression, and undesirable generation of anti-drug antibody (ADA). Such drug may be a protein, a peptide, an antibody, or a gene therapy vector.
The described methods, uses, and compositions may delay the appearance of a symptom associated with the diseases/disorders/conditions, slow the progression of the
diseases/disorders/conditions, alleviate or cure the diseases/disorders/conditions.
In certain embodiments, use of a metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of D-tryptophan as described herein, in conjunction with an immunosuppressant other than the product or an analog thereof may reduce dose and/or
administration frequency of the immunosuppressant, resulting in an alleviated toxicity effects of the immunosuppressant. In one embodiment, alleviation of a toxicity effect refers to no or delayed appearance of the toxicity effect, and/or a toxicity effect at a less severe level or a lower frequency. Such toxicity effects include, for example, one or more of the following: weight gain: hypertension; hyperglycemia, diabetogenic effects; renal toxicity; diarrhea, constipation, nausea or vomiting: heartburn: stomach pain: loss of appetite: headache: uncontrollable shaking of a part of the body: difficulty falling asleep or staying asleep: dizziness: weakness: joint or back pain: rash or itching: burning, pain, numbness, or tingling in the hands or feet; decreased, painful, and/or burning urination; swelling of the hands, arms, feet, ankles, or lower legs; unusual bruising or bleeding; seizures; coma; blurred vision, eye pain, or seeing halos around lights; swelling, rapid weight gain, feeling short of breath; severe depression, feelings of extreme happiness or sadness, changes in personality or behavior, seizure (convulsions); bloody or tarry stools, coughing up blood; pancreatitis (severe pain in upper stomach spreading to back, nausea and vomiting, fast heart rate); low potassium (confusion, uneven heart rate, extreme thirst, increased urination, leg discomfort, muscle weakness or limp feeling); dangerously high blood pressure (severe headache, blurred vision, buzzing in ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure); sleep problems (insomnia), mood changes; increased appetite, gradual weight gain; acne, increased sweating, dry skin, thinning skin, bruising or discoloration; slow wound healing; headache, dizziness, spinning sensation; nausea, stomach pain, bloating; or changes in the shape or location of body fat (especially in arms, legs, face, neck, breasts, and waist). Other toxicity effects and toxicity effects specific to a certain immunosuppressant can be found on Drugs.com or accessdata.fda.gov/
scripts/cder/daf/index . cfm.
In certain embodiments, an“effective amount” of a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of D-tryptophan as provided herein is the amount which achieves desired amelioration of diseases or conditions as described herein and/or alleviation of a toxicity effect of an immunosuppressant. In certain embodiments, an “effective amount” of a metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of tryptophan as provided herein is the amount which achieves one or more of the following endpoints: a delay in appearance of a symptom associated with a disease/disorder/condition as described herein, a slower progression of a
disease/disorder/condition as described herein, an alleviated symptom or no symptom associated with a disease/disorder/condition as described herein, prevention of a disease/disorder/condition (for example, allograft rejection), and alleviation of a toxicity effect associated with an immunosuppressant which includes no or delayed appearance of a toxicity effect, and/or a toxicity effect at a less severe level or a lower frequency.
The following definitions are provided to facilitate an understanding of the present invention.
The term "indolamine dioxygenase (IDO)" is intended to mean IDO-l (indoleamine 2,3- dioxygenase, EC 1.13.11.52), IDO-2 (indoleamine-pyrrole 2,3 dioxygenase-like 1, EC 1.13.11.-) or TDO (tryptophan 2,3-dioxygenase, EC 1.13.11.11) and refers to three different proteins that can catabolize tryptophan. IDO-l can also catabolize serotonin and melatonin although the substrate specificity for IDO-2 and TDO is not so well studied. Metabolites or catabolites from the tryptophan pathway are Tryptophan, N-Formyl-kynurenine, Formylanthranilate,
Anthranilate, L-Kynurenine, D-Kynurenine, 4-(2-Aminophenyl)-2,4-dioxybutanoate, Kynurenic acid, 3-Hydroxy-L-kynurenine, 3-Hydroxy-anthranilate, 3-Metoxy-anthranilate, 4-(2-Amino-3- hydroxy-phenyl)-2,4-dioxobutanoate, Xanthurenate, 8-Metoxy-kurenate, 2- Amino-3 -carboxy- muconate semialdehyde, 2-Aminomuconate semialdehyde, Quimolinic acid, Cinnavalininate, Tryptamine, N-Methyltryptamine, Indoleacetate, 2-Formamino-benzoylacetate, 5-Hydroxy-L- tryptophan, 5-Hydroxy-N-formylkunerine, 5-Hydroxy-kunerine, 5-Hydroxy-kunerenamin, 4,6- Dihydroxy-quinoline, Serotonin, N-Acetyl-serotonin, Melatonin, 6-Hydroxy-melatonin, Formyl- N-acetyl-5-metoxykynurenamine, N-Methylserotonin, Formyl-5-hydroxy-kynurenamine, 5- Metoxytryptamine, 5-Hydroxyindole-acetaldehyde, 5-Hydroxyindoleacetate, 5- Metoxyindoleacetate, or 5-Hydroxyindole-acetylglycine. Agents that potentially enhance the immunosuppressive IDO activity. Examples are D-Kynurenine, 3-hydroxy-kynurenine, anthranilic acid, 3-hydroxy-anthranilic acid, quinolinic acid and picolinic acid. Also
enhancements using synthetic variants of tryptophan catabolites, e.g., N-(3,4,- Dimethoxycinnamoyl) anthranilic acid.
“Tregs” are potent suppressors of T cell mediated immunity in a range of inflammatory conditions, including infectious disease, autoimmunity, pregnancy and tumors (Sakaguchi, S, Nat Immunol 2005; 6:345-352). Mice lacking Tregs die rapidly of uncontrolled autoimmune disorders (Khattri et al. Nat Immunol 2003; 4:337-342). In vivo, a small percentage of Tregs can
control large numbers of activated effector T cells. Although freshly isolated Tregs exhibit minimal constitutive suppressor functions, ligating the T cell antigen receptor (TCR) in vitro (Thornton et al. Eur J Immunol 2004; 34:366-376), or pre-immunizing mice with high-dose self antigen in vivo stimulates Treg suppressor functions (Nishikawa et al. J Exp Med 2005; 201:681- 686).
The term“alloantigen” is defined herein as an antigen present only in an allograft from a allograft donor and capable of inducing the production of an alloantibody response by allograft recipients
The term "immunoprotective" is defined herein as an effect which reduces, arrests, or ameliorates immunological insult and is protective, resuscitative or revivative for affected tissue that has suffered cytotoxic insult from immune cells or inflammation.
The phrase“immunoprotective agent" is herein defined as active ingredient or medicament containing an immune insult treatment dose of active ingredient effective in reducing, preventing, arresting, or ameliorating immune insult and provides protection, resuscitation or revival to affected tissue that has suffered immune mediated insult.
The term "buffer" is intended to mean an aqueous solution containing an acid-base mixture with the purpose of stabilising pH. Examples of buffers are Trizma, Bicine, Tricine, MOPS, MOPSO, MOBS, Tris, Hepes, HEPBS, MES, phosphate, carbonate, acetate, citrate, glycolate, lactate, borate, ACES, ADA, tartrate, AMP, AMPD, AMPSO, BES, CABS, cacodylate, CHES, DIPSO, EPPS, ethanolamine, glycine, HEPPSO, imidazole, imidazolelactic acid, PIPES, SSC, SSPE, POPSO, TAPS, TABS, TAPSO and TES.
The term "diluent" is intended to mean an aqueous or non-aqueous solution with the purpose of diluting the medicament. The diluent may be one or more of saline, water, polyethylene glycol, propylene glycol, ethanol or oils (such as safflower oil, com oil, peanut oil, cottonseed oil or sesame oil).
An excipient may be one or more of carbohydrates, polymers, lipids and minerals.
Examples of carbohydrates include lactose, sucrose, mannitol, and cyclodextrines, which are added to the composition, e.g., for facilitating lyophilisation. Examples of polymers are starch, cellulose ethers, cellulose carboxymethylcellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose, alginates, carageenans, hyaluronic acid and derivatives thereof, polyacrylic acid, polysulphonate, polyethylenglycol/polyethylene oxide,
polyethyleneoxide/polypropylene oxide copolymers, poly vinylalcohol/poly vinylacetate of different degree of hydrolysis, and polyvinylpyrrolidone, all of different molecular weight, which are added to the composition, e.g., for viscosity control, for achieving bioadhesion, or for protecting the lipid from chemical and proteolytic degradation. Examples of lipids are fatty acids, phospholipids, mono-, di-, and triglycerides, ceramides, sphingolipids and glycolipids, all of different acyl chain length and saturation, egg lecithin, soy lecithin, hydrogenated egg and soy lecithin, which are added to the composition for reasons similar to those for polymers. Examples of minerals are talc, magnesium oxide, zinc oxide and titanium oxide, which are added to the composition to obtain benefits such as reduction of liquid accumulation or advantageous pigment properties.
The compositions of the invention may be administrated by any suitable route including oral, sublingual, buccal, nasal, inhalation, parenteral (including intraperitoneal, intraorgan, subcutaneous, intradermal, intramuscular, intra- articular, venous (central, hepatic or peripheral), lymphatic, cardiac, and arterial, with parenteral being the preferred route. The preferred route may vary depending on the condition of the patient.
As described herein, the terms“reduce”“decrease”“alleviate”“ameliorate”“improve” “delay”“earlier”“lower”“mitigate”, any grammatical variation thereof, or any similar terms indication a change, means a variation of about 5 fold, about 2 fold, about 1 fold, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5 % compared to a reference (e.g., a healthy control, a subject having a disease/disorder/condition as described herein, a subject having transplantation, a subject having an autoimmune disease, a subject having a graft versus host disease, an standard immunosuppressant regimen achieving similar or the same immune suppression effect without using the described metabolic breakdown product of tryptophan or an analog thereof), unless otherwise specified.
In certain embodiments, an immunosuppressant is administered to a subject 0, 1, 2, 3, 4,
5, 6, 7, about 1 week (7 days), about 15 days, about 30 days, about 45 days, about 60 days, or longer, prior to or after the administration of the described metabolic breakdown product of tryptophan or an analog thereof. Such immunosuppressant administration may involve administration of one, two or more immunosuppressants (e.g., glucocorticoids, prednelisone, micophenolate mofetil (MMF) and/or sirolimus (i.e., rapamycin)). Additionally, or alternatively, such immunosuppressant(s) may be administrated to a subject in need once, twice or for more
times at the same dose or an adjusted dose. Immunosuppressants for such co-therapy include, but are not limited to, tacrolimus, prednisone, a glucocorticoid, steroids, antimetabolites, T-cell inhibitors, a macrolide ( e.g ., a rapamycin or rapalog), and cytostatic agents including an alkylating agent, an anti-metabolite, a cytotoxic antibiotic, an antibody, or an agent active on immunophilin. The immune suppressant may include a nitrogen mustard, nitrosourea, platinum compound, methotrexate, azathioprine, mercaptopurine, fluorouracil, dactinomycin, an anthracy cline, mitomycin C, bleomycin, mithramycin, IL-2 receptor- (CD25-) or CD3 -directed antibodies, anti-IL-2 antibodies, cyclosporin, tacrolimus, sirolimus, IFN-b, IFN-g, an opioid, or TNF-a (tumor necrosis factor-alpha) binding agent.
The Example below is provided to illustrate certain embodiments of the invention. It is not intended to limit the invention in anyway.
Example 1
Indoleamine 2,3 -dioxygenase (IDO), an enzyme involved in the catabolism of tryptophan, is expressed in certain cells and tissues, particularly in antigen-presenting cells of lymphoid organs and in the placenta. It was shown that IDO prevents rejection of the fetus during pregnancy probably by inhibiting alloreactive T cells, and it was suggested that IDO- expression in antigen-presenting cells may control autoreactive immune responses. Degradation of tryptophan, an essential amino acid required for cell proliferation, was reported to be the mechanism of IDO-induced T cell suppression. As mentioned above, kynurenine is an IDO degradation product.
Kynurenine can be in an L- or D- isomer form. A key difference in D-kynurenine over L- kynurenine is that a key enzyme in L-kynurenine degradation, Kynureninase, is specific to the L- kynurenine isomer and cannot metabolize the D-isomer.21, 22 This feature could be exploited for developing agent which avoid mixed or pro-inflammatory metabolites downstream of L-, but not D-kynurenine, thereby re-routing kynurenine metabolites to aryl hydrocarbon receptor (AHR) agonists. AHR agonists have been suggested to be a key mediator of Foxp3+ regulatory T cell induction and suppressive function.23, 24 AHR receptor knock out mice are also utilized to investigate effects of L- or D- kynurenine.
Our data indicate that exposure to D- and/or L-kynurenine can suppress T cell proliferation. See Figures 1, 3 A and 4A. It was also found that 1 mM of Kynurenine induced T cell apoptosis. See, Figures 3B, 3C, 4A, and 6. T cells from C57BL/6 mice were isolated and evaluated for their response to D- or L- kynurenine treatment in vitro and in vivo as previously reported.25 27 Conventional T cells were stimulated under polarizing conditions to induce formation of mature T cells (for example, cytotoxic, effector and regulatory T cells).
Stabilization of Foxp3+ regulatory T cell phenotype and / or the effects on immune response suppression was also analyzed. No differential effect was observed on Treg. See, Figure 3A. In vivo immunosuppressive effects of D-kynurenine shown in a homeostatic proliferation assay are plotted in Figures 9A to 9C. The results indicate less T cells and CD4+ T cells upon treatment of D- or L-kynurenine in vivo. The rate of weight gain in the kynurenine homoeostatic proliferation experiment was tracked. A slight impairment in weight gain was found with kynurenine treatment (Figures 9D and 9E). Cell death explains most of the T cell phenotypes observed in vitro.
Without wishing to be bound by the theory, we hypothesize that exposure to D- kynurenine weakens key cytotoxic and effector T cell functions. In additional experiments, we co-stimulated and exposed murine and human CD4+ and CD8+ T cells to proliferate (tracked by dye dilution via flow cytometry) to produce cytokines in response to stimulation see, Figures 5A-5B and 6. Both D- or L-kynurenine were assessed for their ability to impair T cell viability(see, Figures 3B, 3C, 4A, and 6)/proliferation (see, Figures 4A) and effector functions including cytokine production (see, Figures 5A-5B and 6).
Studies on metabolic effects of L- or D-kynurenine were performed, indicating decreasing glycolysis and increasing lipid catabolism, which we found to play a key role in kynurenine-induced T cell apoptosis. In one experiment, Tconv were co-stimulated for 16 hours and exposed to 1 mM L- or D-kynurenine for 3 hours. Metabolites were extracted and analyzed by LC-MS. Results are shown in Figures 2A and 2B. The increase in Kynurenic acid is consistent with the expected D-Kynurenine phenotype of Kynureninase resistance.
Additionally, we observed that kynurenine impairs T cell function by augmenting lipid catabolism. Our studies identified that kynurenine impair T cell glycolysis, which selectively impairs Teff and CTL but spares Treg, creating immunosuppressive conditions.
Example 2
Effects of D-Kynurenine
LC-MS and [13C6] glucose tracing studies are performed in order to reveal depletion of post-GAPDH glycolytic intermediates with or without L-, D- or mixed isoforms of kynurenine. Briefly, Tconv were co-stimulated and cultured in low glucose medium (30 mg/dL) for 48 hours with or without L-, D- or mixed isoforms of kynurenine, and 1 mM heptelidic acid (GAPDHi) or DMSO vehicle control.
Additionally, Tconv and CTL are co-stimulated and cultured with or without L-, D- or mixed isoforms of kynurenine.
Tconv are also stimulated with CD3e/CD28 for 16 hours and then labeled with 60 mg/dL [13C6] D-glucose or [13C3] Pyruvate for 2 hr with or without L-, D- or mixed isoforms of kynurenine.
Metabolites are extracted and analyzed via LC-MS, resulting a heatmap showing increased and decreased glycolytic inter-mediates ion count normalized to control. Glucose derivatives are investigated through [13C6] D-glucose. The effect of kynurenine on glucose, glutamine and fatty acid metabolism is characterized through heavy carbon [13C] metabolic flux tracer studies. Also assessed are the direction of the Krebs cycle (reductive/oxidative), redox- dependent rerouting of metabolic pathways and effects on the production of immune regulatory metabolites. Glycolytic intermediates can be re-routed to e.g. the pentose phosphate pathway55, one carbon metabolism56, or the methylglyoxal pathway57 60. Such altered pathways can be functionally important to T cell function61. The amount of heavy carbon isotopes in citrate is tracked, indicating how citrate was formed out of [13Cs] L-glutamine (M+5 reductive vs. M+4 oxidative). Also tracked are other glutamine derived metabolites such as 2-HG.
The effects of kynurenine treatment on lipid metabolism was also determined. Fatty acid metabolism, both b-oxidation and fatty acid synthesis, are crucial metabolic processes that are NAD:NADH regulated, and affect T cell differentiation and function35, 61 63. While [13C6] D- glucose and [13Cs] L-glutamine inform fatty acid synthesis, [13C½] palmitate tracing allows us to determine the kinetics of b -oxidation under kynurenine exposure.
The data show that a 3-hour exposure to kynurenine depleted fatty acids from cell media, which we found to be causally related to T cell apoptosis (Figures 7 and 8A). Our data showed that kynurenine augments lipid catabolism and palmitate depletion (Figure 7). Restoring
oleate/palmitate rescues apoptosis, indicating fatty acid depletion is a reversible cause of kynurenine induced T cell apoptosis. See, Figure 8 A. It is noted that increased number of cells treated per well and addition of albumin (for example, bovine serum albumin (BSA)) also show some effects. See Figure 8B. Albumin partially rescue the apoptosis while cell number affects response.
These data pointed to an important role for lipid catabolism in kynurenine rich environments. We observed, that 3-day co-stimulated Teffs ±1 mM L- or D-kynurenine had 98.9 ±0.55 or 97.3 ±0.55% cell death (vs. 69.7 ±18.84% in untreated Teff, 4/grp). Addition of 0.2-0.6 mM oleate/palmitate rescued the apoptosis phenotype, restoring Teff viability and proliferation. See, Figures 7 and 8A. Our results showed the immune modulatory potential of TME fatty acids, and indicated the possible use of kynurenines to induce lipid catabolism therapeutically.
Example 3
Evaluation of D-Kynurenine as an Immunosuppressive Therapy in vivo
- Autoimmune Disease
To assess whether kynurenines alleviate symptoms of autoimmune disease, autoimmune colitis is induced by chronic administration of dextran sulfate sodium to C57BL/6 mice and adoptive transfer of CD4+ Tconv isolated from wildtype (WT) C57BL/6 mice into
immunodeficient B6/Ragl 7 recipients. Clinical parameters of colitis are determined and inflammation assessed using methods which include, but are not limited to histology and flow cytometry.25 These studies demonstrate the utility of D- and L-kynurenine as immunosuppressive agents.
Example 4
Evaluation of D-Kynurenine as an Immunosuppressive Therapy in vivo - Kidney Transplant Model and Cardiac Transplant Model
In order to access the role of D-/L- kynurenine in supporting and reducing
immunosuppressive therapy in transplantation as well as evaluate if D-/L- kynurenine affects allograft function, metabolism, and transplant tolerance, two murine animal models are utilized. In the first kidney transplant model, BALB/c kidneys are transplanted to nephrectomized C57BL/6 recipients who depend on allograft function to survive.29 A second BALB/c to
C57BL/6 cardiac allograft model is also used to determine if the dose of tacrolimus (an
immunosuppressant) required to maintain an allograft can be lowered with kynurenine (D- or L- or mixed isoform) treatment. The murine kidney transplant model is not as immunogenic as the cardiac transplant model. In our hands, 40% of the recipients survived for more than 80 days.
This indicates that the kidney transplant model allows investigating long-term differences between the D-/L- kynurenine-treated vs. the control groups than the cardiac transplant model16.
To minimize effects of microbiota32, home-growing mice are used for these in vivo studies. 5-10 or 10-15 mice are used per group of both female and male mice. Statistical analysis (normal distribution testing, comparative statistics) assesses significance.
Na kynurenine in D- or L- or mixed isoform is provided through the drinking water, food, and/or intraperitoneal {i.p.) injections. In some experiments, Kynurenine in D- or L- or mixed isoform is administered through i.p. injections (30 mg/kg/d), or enteral administration via diet (300 mg/kg/d, more details about this administration can be found in reference 30). NaCl (vs. no additive) is used as a negative control. Animal survival, allograft function and metabolites are monitored, while graft histology and intragraft lymphocytes are evaluated to assess mechanisms linked with graft rejection or survival. For example, median allograft survival is calculated;
quantitative data showing BUN, creatinine, calcium, hematocrit and LC-MS assessment of serum kynurenine split product is acquired; and antigen- specific T cell responses is evaluated.
In order to address whether kynurenine prolongs renal allograft dependent survival & allograft function, C57BL/6 mice are transplanted with BALB/c kidneys. The native kidneys are removed after 7 days. As previously reported 28 , removal of the native kidneys makes the mice dependent on renal allograft function to survive. We track hematocrit, creatinine, and other important parameters on metabolism and renal function with 70 pL of blood (Chem8, Abbott) which is obtained weekly. This quantity of blood removal is well tolerated and does not affect hematologic parameters28,50.
Further, Kynurenine treatment induced donor specific tolerance is evaluated. Mice developing longer than 100 days’ allograft survival receive a cervical 3rd party (C3H, H-2k) or a BALB/C (H-2d re-exposure) cardiac allograft to the neck28. Neck cardiac allograft survival are tracked by palpation, histology and immunohistochemistry28.
Further, reduction in using conventional immunosuppressive drugs in MHC-mismatched transplant models is also investigated.
In a second model, it is investigated whether Kynurenine can allow to lower the dose of conventional immunosuppressive therapy ( i.e . tacrolimus). C57BL/6 mice are transplanted with B ALB/c abdominal cardiac allografts16, 51, 52. The recipients were treated with a subtherapeutic dose of tacrolimus (1 mg/kg/d), on which the mice would be expected to reject53. In our previous studies, we have observed, that 1 mg/kg of tacrolimus administered to C57BL/6 mice had barely any effect on T cell function54. Kynurenine administration is performed as indicated above and tested if it can prolong cardiac allograft survival. Body NAD:NADH ratios are further investigated via collecting liver, spleen, colon, and allograft tissue in liquid nitrogen, and later measuring NAD:NADH16 as well as histone acetylation/methylation.
Additionally, transplant-induced weight gain and diabetes are studied in these two models. Detailed methods can be found in the following Example.
Example 5
Kynurenine Treatment Mitigates Prednisone Induced Weight Gain and Hyperglycemia
6-week-old female Ragl_/_ mice were injected i.p. with 1 x 106 of B6 Tconv cells on Day 0. Starting on Day 7, D-Kynurenine, L-Kynurenine or control was administered i.p. at a dose of 30 mg/kg/day on Days 7-11, 14-18 and 21-24. Body weight was measured on days 0, 8, 16, 18, 23 and 25. On Day 25, mice were sacrificed. Serum and other tissues were harvested for further analysis. Immunosuppressive response in vivo is also evaluated. We observed that Kynurenine treatment slowed weight gain, suggesting that Kynurenine may affect immunosuppressant associated weight gain. See, Figures 9D and 9E.
Further, an established model of assessing prednisone induced weight gain and hyperglycemia31 is used with modifications to control for the effects of gender and microbiota32. Home-bred C57BL/6 are used. Regular chow diet providing 25% kcal from fat is provided to mice after weaning. Four weeks after weaning (i.e., about 9 weeks to 12 weeks of age), all mice (both genders) are exposed to a high fat diet (45% kcal from fat) with high dose
methylprednisolone (10 mg/kg/g i.p.) injections, with either Na D-Kynurenine i.p. injections (30 mg/kg/d) or vehicle control. Body weight is tracked. Serum glucose and insulin are measured weekly. A glucose tolerance test is performed at week 12, after which serum and tissue are collected. Results relating to weight, hyperglycemia, or insulin resistance phenotype are analyzed
to evaluate the alleviation of D-kynurenine treatment. T cell metabolism, caloric intake and energy expenditure are also explored.
Instead of i.p. injections for administering D-Kynurenine, enteral formulations which could achieve even higher doses are investigated using the same experimental setting.
Example 6
Metabolic Effects of D-Kynurenine
The metabolic effect of kynurenine (L-, D- or mixed isoform) is evaluated on transplant recipient metabolism. The effects of kynurenine on glucose, glutamine and fatty acid metabolism is characterized through heavy carbon [13C] metabolic flux tracer studies. Also assessed are the direction of the Krebs cycle (reductive/oxidative), redox-dependent rerouting of metabolic pathways and effects on the production of immune regulatory metabolites.
Metabolic pathways affected by kynurenine are identified, which can include T cell glycolysis (cytokine production,13, 33 or intracellular calcium15), de novo lipogenesis of Thl7 T cells indicating that targeting acetyl-CoA carboxylase 1 shifts Thl7 formation towards Foxp3+ Treg35, the reverse Krebs cycle which is important to highly proliferating cells under hypoxic conditions36 affecting malate dehydrogenase activity and favoring a-ketoglutarate metabolism to L-2-HG and subsequent effects on DNA methylation37, the metabolic sequelae of conventional immunosuppression such as tacrolimus and prednisone (weight gain, diabetogenic)38, and more34. Without wishing to be bound by the theory, kynurenine treatment may alleviate some of these problems by dose reduction of conventional immunosuppressants, and maybe by counteracting certain co-morbid pathologies, such as weight gain.
Additionally, co-stimulated Tconv, CTL, & Tregs, adding L- or D- kynurenine. The T cells are labeled using heavy carbon tracers [13C6] D-glucose, [13Cs] L-glutamine, and [13C½] palmitate each in separate experiments (all in biological triplicate at minimum). After labeling, metabolites are methanol-extracted and submitted for LC/MS derivative analysis. Methods were detailed16, 39 4(443.
References
1. Lo, M.S. and G.C. Tsokos, Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann N Y Acad Sci, 2012. 1247: p. 138-52.
. Van Assche, G., S. Vermeire and P. Rutgeerts, Immunosuppression in inflammatory bowel disease: traditional, biological or both? Curr Opin Gastroenterol, 2009. 25(4): p. 323-8.
3. McDonald-Hyman, C., L.A. Turka and B.R. Blazar, Advances and challenges in
immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med, 2015. 7(280): p. 280rv2.
. Flowers, M.E. and P.J. Martin, How we treat chronic graft-versus-host disease. Blood, 2015. 125(4): p. 606-15.
5. Chauhan, B.F. and F.M. Ducharme, Anti-leukotriene agents compared to inhaled
corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev, 2012. 5: p. CD002314.
6. Westhoff, T.H. and M. van der Giet, Tacrolimus in the treatment of idiopathic nephrotic syndrome. Expert Opin Investig Drugs, 2007. 16(7): p. 1099-110.
. Naesens, M., D.R. Kuypers and M. Sarwal, Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol, 2009. 4(2): p. 481-508.
8. Fishman, J.A., Infection in solid-organ transplant recipients. N Engl J Med, 2007.
357(25): p. 2601-14.
9. Singer, K., E. Gottfried, M. Kreutz and A. Mackensen, Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother, 2011. 60(3): p. 425-31.
10. Zamanakou, M., A.E. Germenis and V. Karanikas, Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett, 2007. 111(2): p. 69-75.
11. Adams, S., N. Braidy, A. Bessede, B.J. Brew, R. Grant, C. Teo and G.J. Guillemin, The kynurenine pathway in brain tumor pathogenesis. Cancer Res, 2012. 72(22): p. 5649-57.
12. Macintyre, A.N., V.A. Gerriets, A.G. Nichols, R.D. Michalek, M.C. Rudolph, D.
Deoliveira, S.M. Anderson, E.D. Abel, B.J. Chen, L.P. Hale and J.C. Rathmell, The glucose transporter Glutl is selectively essential for CD4 T cell activation and effector function. Cell Metab, 2014. 20(1): p. 61-72.
13. Chang, C.H., J.D. Curtis, L.B. Maggi, Jr., B. Faubert, A.V. Villarino, D. O'Sullivan, S.C.
Huang, G.J. van der Windt, J. Blagih, J. Qiu, J.D. Weber, E.J. Pearce, R.G. Jones and E.L. Pearce, Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell, 2013. 153(6): p. 1239-51.
14. Chang, C.H., J. Qiu, D. O'Sullivan, M.D. Buck, T. Noguchi, J.D. Curtis, Q. Chen, M. Gindin, M.M. Gubin, G.J. van der Windt, E. Tone, R.D. Schreiber, E.J. Pearce and E.L. Pearce, Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell, 2015. 162(6): p. 1229-41.
15. Ho, P.C., J.D. Bihuniak, A.N. Macintyre, M. Staron, X. Liu, R. Amezquita, Y.C. Tsui, G.
Cui, G. Micevic, J.C. Perales, S.H. Kleinstein, E.D. Abel, K.L. Insogna, S. Feske, J.W. Locasale, M.W. Bosenberg, J.C. Rathmell and S.M. Kaech, Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell, 2015. 162(6): p. 1217-28.
16. Angelin, A., L. Gil-de-Gomez, S. Dahiya, J. Jiao, L. Guo, M.H. Levine, Z. Wang, W.J.
Quinn, 3rd, P.K. Kopinski, L. Wang, T. Akimova, Y. Liu, T.R. Bhatti, R. Han, B.L. Laskin, J.A. Baur, I.A. Blair, D.C. Wallace, W.W. Hancock and U.H. Beier, Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate
Environments. Cell Metab, 2017. 25(6): p. 1282-1293 e7.
17. Sugiura, A. and J.C. Rathmell, Metabolic Barriers to T Cell Function in Tumors. J
Immunol, 2018. 200(2): p. 400-407.
18. Fallarino, F., U. Grohmann, C. Vacca, R. Bianchi, C. Orabona, A. Spreca, M.C. Fioretti and P. Puccetti, T cell apoptosis by tryptophan catabolism. Cell Death Differ, 2002.
9(10): p. 1069-77.
19. Fallarino, F., U. Grohmann, S. You, B.C. McGrath, D.R. Cavener, C. Vacca, C. Orabona, R. Bianchi, M.L. Belladonna, C. Volpi, P. Santamaria, M.C. Fioretti and P. Puccetti, The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol, 2006. 176(11): p. 6752-61.
0. Li, L., L. Huang, H.P. Lemos, M. Mautino and A.L. Mellor, Altered tryptophan
metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases. Front Immunol, 2012. 3: p. 109.
1. Loh, H.H. and C.P. Berg, Conversion of D -tryptophan to nicotinic acid in the rat. J Nutr, 1971. 101(12): p. 1601-6.
2. Wang, X.D., F.M. Notarangelo, J.Z. Wang and R. Schwarcz, Kynurenic acid and 3- hydroxykynurenine production from D-kynurenine in mice. Brain Res, 2012. 1455: p. 1-9.
23. Mezrich, J.D., J.H. Fechner, X. Zhang, B.P. Johnson, W.J. Burlingham and C.A.
Bradfield, An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol, 2010. 185(6): p. 3190-8.
24. Quintana, F.J., A.S. Basso, A.H. Iglesias, T. Korn, M.F. Farez, E. Bettelli, M. Caccamo, M. Oukka and H.L. Weiner, Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature, 2008. 453(7191): p. 65-71.
25. Akimova, T., H. Xiao, Y. Liu, T.R. Bhatti, J. Jiao, E. Eruslanov, S. Singhal, L. Wang, R.
Han, K. Zacharia, W.W. Hancock and U.H. Beier, Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T -regulatory cells. Mucosal Immunol, 2014. 7(5): p. 1209-20.
26. Beier, U.H., L. Wang, R. Han, T. Akimova, Y. Liu and W.W. Hancock, Histone
deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms. Sci Signal, 2012. 5(229): p. ra45.
27. Beier, U.H., L. Wang, T.R. Bhatti, Y. Liu, R. Han, G. Ge and W.W. Hancock, Sirtuin-1 targeting promotes Foxp3+ T -regulatory cell function and prolongs allograft survival. Mol Cell Biol, 2011. 31(5): p. 1022-9.
28. Levine, M.H., Z. Wang, H. Xiao, J. Jiao, L. Wang, T.R. Bhatti, W.W. Hancock and U.H.
Beier, Targeting Sirtuin-1 prolongs murine renal allograft survival and function. Kidney Int, 2016. 89(5): p. 1016-26. PMCID: PMC4834143
29. Bax, B.E. and D.L. Bloxam, Energy metabolism and glycolysis in human placental
trophoblast cells during differentiation. Biochim Biophys Acta, 1997. 1319(2-3): p. 283- 92
30. Pocivavsek, A., M.A. Thomas, G.I. Elmer, J.P. Bruno and R. Schwarcz, Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. Psychopharmacology (Berl), 2014. 231(14): p. 2799-809. PMCID: PMC4074218
31. Laskewitz, A.J., T.H. van Dijk, A. Grefhorst, M.J. van Lierop, M. Schreurs, V.W. Bloks, D.J. Reijngoud, W.H. Dokter, F. Kuipers and A.K. Groen, Chronic prednisolone treatment aggravates hyperglycemia in mice fed a high-fat diet but does not worsen dietary fat-induced insulin resistance. Endocrinology, 2012. 153(8): p. 3713-23
32. Lieber, A.D., U.H. Beier, H. Xiao, B J. Wilkins, J. Jiao, X.S. Li, R.C. Schugar, C.M. Strauch, Z. Wang, J.M. Brown, S.L. Hazen, N.A. Bokulich, K.V. Ruggles, T. Akimova, W.W. Hancock and M J. Blaser, Loss ofHDAC6 alters gut microbiota and worsens obesity. FASEB J, 2019. 33(1): p. 1098-1109
33. Menk, A.V., N.E. Scharping, R.S. Moreci, X. Zeng, C. Guy, S. Salvatore, H. Bae, J. Xie, H.A. Young, S.G. Wendell and G.M. Delgoffe, Early TCR Signaling Induces Rapid Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions. Cell Rep, 2018. 22(6): p. 1509-1521
34. Buck, M.D., R.T. Sowell, S.M. Kaech and E.L. Pearce, Metabolic Instruction of
Immunity. Cell, 2017. 169(4): p. 570-586
35. Berod, L., C. Friedrich, A. Nandan, J. Freitag, S. Hagemann, K. Harmrolfs, A. Sandouk, C. Hesse, C.N. Castro, H. Bahre, S.K. Tschimer, N. Gorinski, M. Gohmert, C.T. Mayer,
J. Huehn, E. Ponimaskin, W.R. Abraham, R. Muller, M. Lochner and T. Sparwasser, De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med, 2014. 20(11): p. 1327-33
36. Filipp, F.V., D.A. Scott, Z.A. Ronai, A.L. Osterman and J.W. Smith, Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res, 2012. 25(3): p. 375-83. PMCID:
PMC3329592
37. Intlekofer, A.M., R.G. Dematteo, S. Venneti, L.W. Finley, C. Lu, A.R. Judkins, A.S.
Rustenburg, P.B. Grinaway, J.D. Chodera, J.R. Cross and C.B. Thompson, Hypoxia Induces Production of L-2 -Hydroxy glutar ate. Cell Metab, 2015. 22(2): p. 304-11.
PMCID: PMC4527873
38. Shivaswamy, V., B. Boemer and J. Larsen, Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. Endocr Rev, 2016. 37(1): p. 37-61. PMCID:
PMC4740345
39. Hui, S., J.M. Ghergurovich, R.J. Morscher, C. Jang, X. Teng, W. Lu, L.A. Esparza, T.
Reya, Z. Le, J. Yanxiang Guo, E. White and J.D. Rabinowitz, Glucose feeds the TCA cycle via circulating lactate. Nature, 2017. 551(7678): p. 115-118. PMCID:
PMC5898814
40. Liu, L., X. Su, W.J. Quinn, 3rd, S. Hui, K. Krukenberg, D.W. Frederick, P. Redpath, L. Zhan, K. Chellappa, E. White, M. Migaud, T.J. Mitchison, J.A. Baur and J.D.
Rabinowitz, Quantitative Analysis of NAD Synthesis-Breakdown Fluxes. Cell Metab, 2018. 27(5): p. l067-l080.e5. PMCID: PMC5932087
41. Jang, C., L. Chen and J.D. Rabinowitz, Metabolomics and Isotope Tracing. Cell, 2018.
173(4): p. 822-837
42. Frederick, D.W., E. Loro, L. Liu, A. Davila, Jr., K. Chellappa, I.M. Silverman, W.J.
Quinn, 3rd, S.J. Gosai, E.D. Tichy, J.G. Davis, F. Mourkioti, B.D. Gregory, R.W.
Dellinger, P. Redpath, M.E. Migaud, E. Nakamaru-Ogiso, J.D. Rabinowitz, T.S. Khurana and J.A. Baur, Loss of NAD Homeostasis Leads to Progressive and Reversible
Degeneration of Skeletal Muscle. Cell Metab, 2016. 24(2): p. 269-82. PMCID:
PMC4985182
43. Jang, C., S.F. Oh, S. Wada, G.C. Rowe, L. Liu, M.C. Chan, J. Rhee, A. Hoshino, B. Kim, A. Ibrahim, L.G. Baca, E. Kim, C.C. Ghosh, S.M. Parikh, A. Jiang, Q. Chu, D.E.
Forman, S.H. Lecker, S. Krishnaiah, J.D. Rabinowitz, A.M. Weljie, J.A. Baur, D.L.
Kasper and Z. Arany, A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat Med, 2016. 22(4): p. 421-6. PMCID:
PMC4949205
44. Loh, H.H. and C.P. Berg, Conversion of D -tryptophan to nicotinic acid in the rat. J Nutr, 1971. 101(12): p. 1601-6
45. Wang, X.D., F.M. Notarangelo, J.Z. Wang and R. Schwarcz, Kynurenic acid and 3- hydroxykynurenine production from D-kynurenine in mice. Brain Res, 2012. 1455: p. 1-9. PMCID: 3340494
46. Santamaria, A., C. Rios, F. Solis-Hemandez, J. Ordaz-Moreno, L. Gonzalez-Reynoso, M.
Altagracia and J. Kravzov, Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology, 1996. 35(1): p. 23-8
47. Chiarugi, A., R. Carpenedo and F. Moroni, Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase. J Neurochem, 1996. 67(2): p. 692-8
48. Stone, T.W., C.M. Forrest and L.G. Darlington, Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J, 2012. 279(8): p. 1386-97
49. Quintana, F.J., A.S. Basso, A.H. Iglesias, T. Korn, M.F. Farez, E. Bettelli, M. Caccamo, M. Oukka and H.L. Weiner, Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature, 2008. 453(7191): p. 65-71
50. Raabe, B.M., J.E. Artwohl, J.E. Purcell, J. Lovaglio and J.D. Fortman, Effects of weekly blood collection in C57BL/6 mice. J Am Assoc Lab Anim Sci, 2011. 50(5): p. 680-5. PMCID: 3189672
51. Beier, U.H., A. Angelin, T. Akimova, L. Wang, Y. Liu, H. Xiao, M.A. Koike, S.A.
Hancock, T.R. Bhatti, R. Han, J. Jiao, S.C. Veasey, C.A. Sims, J.A. Baur, D.C. Wallace and W.W. Hancock, Essential role of mitochondrial energy metabolism in Foxp3(+) T- regulatory cell function and allograft survival. FASEB J, 2015. 29(6): p. 2315-26.
PMCID: PMC4447222
52. Beier, U.H., L. Wang, T.R. Bhatti, Y. Liu, R. Han, G. Ge and W.W. Hancock, Sirtuin-1 targeting promotes Foxp3+ T -regulatory cell function and prolongs allograft survival. Mol Cell Biol, 2011. 31(5): p. 1022-9. PMCID: PMC3067815
53. Wang, Y., Q. Qin, J. Chen, X. Kuang, J. Xia, B. Xie, F. Wang, H. Liang and Z. Qi,
Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice. Transpl Immunol, 2009. 22(1-2): p. 5-11
54. Laskin, B.L., J. Jiao, H.J. Baluarte, S. Amaral, S.L. Furth, T. Akimova, W.W. Hancock, M.H. Levine, P.P. Reese and U.H. Beier, The Effects of Tacrolimus on T-Cell
Proliferation Are Short-Lived: A Pilot Analysis of Immune Function Testing. Transplant Direct, 2017. 3(8): p. el99. PMCID: PMC5540637
55. Yang, Z., Y. Shen, H. Oishi, E.L. Matteson, L. Tian, J.J. Goronzy and C.M. Weyand, Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis. Sci Transl Med, 2016. 8(331): p. 33lra38. PMCID: PMC5074090
56. Ma, E.H., G. Bantug, T. Griss, S. Condotta, R.M. Johnson, B. Samborska, N. Mainolfi, V. Suri, H. Guak, M.L. Balmer, M.J. Verway, T.C. Raissi, H. Tsui, G. Boukhaled, S. Henriques da Costa, C. Frezza, C.M. Krawczyk, A. Friedman, M. Manfredi, M.J. Richer, C. Hess and R.G. Jones, Serine Is an Essential Metabolite for Effector T Cell Expansion. Cell Metab, 2017. 25(2): p. 345-357
57. Ewaschuk, J.B., J.M. Naylor and G.A. Zello, D-lactate in human and ruminant metabolism. J Nutr, 2005. 135(7): p. 1619-25
58. Adeva-Andany, M., M. Lopez-Ojen, R. Funcasta-Calderon, E. Ameneiros-Rodriguez, C.
Donapetry-Garcia, M. Vila-Altesor and J. Rodriguez-Seijas, Comprehensive review on lactate metabolism in human health. Mitochondrion, 2014. 17: p. 76-100
59. Thornalley, P.J., The glyoxalase system: new developments towards functional
characterization of a metabolic pathway fundamental to biological life. Biochem J, 1990. 269(1): p. 1-11. PMCID: 1131522
60. Kalapos, M.P., Methylglyoxal in living organisms: chemistry, biochemistry, toxicology and biological implications. Toxicol Lett, 1999. 110(3): p. 145-75
61. Almeida, L., M. Lochner, L. Berod and T. Sparwasser, Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol, 2016. 28(5): p. 514-524
62. Raud, B., P.J. McGuire, R.G. Jones, T. Sparwasser and L. Berod, Fatty acid metabolism in CD8(+) T cell memory: Challenging current concepts. Immunol Rev, 2018. 283(1): p. 213-231
63. Lochner, M., L. Berod and T. Sparwasser, Fatty acid metabolism in the regulation of T cell function. Trends Immunol, 2015. 36(2): p. 81-91
While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. It will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the scope of the present invention, as set forth in the following claims.
Claims
1. A composition comprising a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan, and at least one immunosuppressant in a pharmaceutically acceptable carrier, each in an effective amount for use in the treatment of autoimmune disease in a subject, wherein said product is D-kynurneine which is not associated with brain toxicity.
2. A composition comprising a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan, and one or more alloantigens present in the allograft in a pharmaceutically acceptable carrier, each in an effective amount for use in preventing allograft rejection in a subject, wherein said product is D-kynurneine which is not associated with brain toxicity.
3. The composition according to claim 2, wherein the composition further comprises at least one immunosuppressant.
4. A composition comprising a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan and at least one immunosuppressant in a pharmaceutically acceptable carrier, for use in the treatment of graft versus host disease in a subject, wherein said product is D-kynumeine.
5. The composition according to claim 4, wherein the subject has received a bone marrow transplant, or a kidney transplant, or a liver transplant, or a cardiac transplant.
6. The composition according to any one of claims 1 to 5, wherein the
immunosuppressant is not a metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of tryptophan.
7. The composition according to any one of claims 1 and 3 to 6, whereby the metabolic breakdown product of D-tryptophan or an analog thereof reduces administration frequency of the immunosuppressant.
8. The composition according to any one of claims 1 and 3 to 7, whereby the D- kynumeine also alleviates toxicity of the immunosuppressant absent brain toxicity obsvered with L- kynurenine is administered.
9. The composition according to any one of claims 1 and 3 to 8, whereby the metabolic breakdown product of tryptophan or an analog thereof improves specificity of the immunosuppressant while preserving the subject’s immune response to infection and cancer.
10. The composition according to any one of claims 1 to 9, wherein the composition further comprises a buffer, a diluent, or an excipient.
11. The composition according to any one of claims 1 to 10, wherein the composition is suitable for an administration via a route selected from the group consisting of parenteral, oral, sublingual, buccal, nasal, inhalation, intraperitoneal, intraorgan, subcutaneous, intradermal, intramuscular, intra-articular, venous, lymphatic, cardiac, and arterial.
12. Use of a metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of D-tryptophan, as a medicament for modulating immune suppression mediated by T cells in a subject in need thereof, wherein said product is D- kynumeine.
13. Use of a metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of tryptophan, as a medicament for the treatment of autoimmune disease in a subject, wherein said product is D-kynumeine which does exhibit brain toxicity observed when L- kynurenine is used.
14. Use of a metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of tryptophan, and optionally, one or more alloantigens present in the allograft, as a medicament for preventing allograft rejection in a subject, wherein said product is D-kynurneine which does exhibit brain toxicity observed when L- kynurenine is used.
15. Use of a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan in a pharmaceutically acceptable carrier, as a medicament for the treatment of graft versus host disease in a subject, wherein said product is D-kynumeine, which does exhibit brain toxicity observed when L- kynurenine is used.
16. The use according to claim 15, wherein the subject has received a bone marrow transplant, or a kidney transplant, or a liver transplant, or a cardiac transplant.
17. The use according to any one of claims 12 to 16, wherein the subject further receives at least one immunosuppressant which is not a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan.
18. Use of a metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of D-tryptophan and at least one immunosuppressant, as a medicament for modulating immune suppression mediated by T cells in a subject in need, or for the treatment of autoimmune disease in a subject in need, or for the treatment of autoimmune disease in a subject in need, or for use in preventing allograft rejection in a subject, or for use in the treatment of graft versus host disease in a subject, and wherein the immunosuppressant is not a metabolic breakdown product of tryptophan or an analog a metabolic breakdown product of tryptophan.
19. The use according to claim 18, wherein the product is D-kynurneine which does exhibit brain toxicity observed with L-kynurneine is administered.
20. The use according to any one of claims 12 to 19, wherein the metabolic breakdown product of tryptophan or an analog thereof reduces dose, or administration frequency, of the immunosuppressant.
21. The use according to any one of claims 12 to 20, wherein the metabolic breakdown product of tryptophan or an analog thereof alleviates toxicity of the
immunosuppressant, or wherein the metabolic breakdown product of tryptophan or an analog thereof improves specificity of the immunosuppressant and preserves the subject’s immune response to infection and cancer.
22. The use according to any one of claims 12 to 21, wherein the metabolic breakdown product of tryptophan or an analog thereof is in a composition which further comprises a buffer or a diluent or an excipient.
23. The use according to any one of claims 12 to 22, wherein the metabolic breakdown product of tryptophan or an analog thereof is suitable for administration via a route selected from the group consisting of parenteral, oral, sublingual, buccal, nasal, inhalation, intraperitoneal, intraorgan, subcutaneous, intradermal, intramuscular, intra- articular, venous, lymphatic, cardiac, and arterial.
24. Use of a metabolic breakdown product of tryptophan or an analog thereof for preparing a medicament.
25. A method of modulating immune suppression mediated by regulatory T cells (Tregs) in a subject, comprising administering to the subject a metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of D-tryptophan, in an amount effective to suppress undesirable immune responses, wherein said product is D-kynurneine which does exhibit brain toxicity observed with L-kynurneine is administered.
26. A method for the treatment of autoimmune disease in a subject in need thereof, comprising administering to the subject a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan, and optionally, one or more alloantigens present in the allograft, wherein said product is D-kynurneine which does exhibit brain toxicity observed with L-kynurneine is administered.
27. A method of preventing allograft rejection in a subject, comprising administering to the subject a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan, and optionally, one or more alloantigens present in the allograft, wherein said product is D-kynurneine which does exhibit brain toxicity observed with L-kynumeine is administered.
28. A method of preventing graft versus host disease in a recipient, comprising administering to the donor a metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan, and one or more alloantigens present in the recipient, wherein the metabolic breakdown product of tryptophan, or an analog of a metabolic breakdown product of tryptophan, and the one or more alloantigens present in the recipient are administered to the donor prior to obtaining donor cells from the donor; obtaining donor cells from the donor; and administering the donor cells to the recipient, wherein said product is D- kynumeine which does exhibit brain toxicity observed with L-kynurneine is administered.
29. The method according to any one of claims 25 to 28, wherein said product is administered via a route selected from the group consisting of parenteral, oral, sublingual, buccal, nasal, inhalation, intraperitoneal, intraorgan, subcutaneous, intradermal, intramuscular, intra- articular, venous, lymphatic, cardiac, and arterial.
30. A method of modulating immune suppression mediated by T cells in a subject, comprising administering to the subject a metabolic breakdown product of D-tryptophan, or an analog of a metabolic breakdown product of D-tryptophan, in an amount effective to suppress undesirable immune responses, wherein said product is D-kynumeine which does exhibit brain toxicity observed with L-kynumeine is administered.
31. The composition, use or method of any of the previous claims, wherein said immunosuppressant is one or more of tacrolimus, prednisone, a glucocorticoid, a steroid, antimetabolites, T-cell inhibitors, a macrolide, rapamycin, rapalog, a cytostatic agent, an alkylating agent, an anti-metabolite, a cytotoxic antibiotic, an antibody, or an agent active on immunophilin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862731660P | 2018-09-14 | 2018-09-14 | |
US62/731,660 | 2018-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020056410A1 true WO2020056410A1 (en) | 2020-03-19 |
Family
ID=69777929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/051298 WO2020056410A1 (en) | 2018-09-14 | 2019-09-16 | Compositions and methods for modulating immunosuppression |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020056410A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012099441A2 (en) * | 2011-01-21 | 2012-07-26 | 인제대학교산학협력단 | Immune response inhibiting composition containing stem cells expressing tryptophan metabolizing enzyme genes |
-
2019
- 2019-09-16 WO PCT/US2019/051298 patent/WO2020056410A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012099441A2 (en) * | 2011-01-21 | 2012-07-26 | 인제대학교산학협력단 | Immune response inhibiting composition containing stem cells expressing tryptophan metabolizing enzyme genes |
Non-Patent Citations (2)
Title |
---|
NOTARANGELO ET AL.: "Role of D-amino acid oxidase in the production of kynurenine pathway metabolites from D-tryptophan in mice", JOURNAL OF NEUROCHEMISTRY, vol. 136, no. 4, 13 January 2016 (2016-01-13), XP055695168, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902784> [retrieved on 20191029] * |
RADU ET AL.: "Immunosuppressive effect of tryptophan metabolites in composite tissue allotransplantation", PLASTIC AND RECONSTRUCTIVE SURGERY, vol. 119, no. 7, June 2007 (2007-06-01), Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pubmed/17519695> [retrieved on 20191107] * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2863369T3 (en) | Immunoablative therapies | |
Huang et al. | Protection against acetaminophen-induced acute liver failure by omentum adipose tissue derived stem cells through the mediation of Nrf2 and cytochrome P450 expression | |
Nagao et al. | Evaluation of a new type of nano-sized carbon monoxide donor on treating mice with experimentally induced colitis | |
CN109640959B (en) | Targeting the innate immune system to induce long-term tolerance and address macrophage accumulation in atherosclerosis | |
Li et al. | Rapamycin relieves inflammation of experimental autoimmune encephalomyelitis by altering the balance of Treg/Th17 in a mouse model | |
Siska et al. | Kynurenine induces T cell fat catabolism and has limited suppressive effects in vivo | |
Crowther et al. | Metabolic regulation of immune responses to mycobacterium tuberculosis: A spotlight on l-arginine and l-tryptophan metabolism | |
Chen et al. | Short chain fatty acids inhibit endotoxin-induced uveitis and inflammatory responses of retinal astrocytes | |
JP2019516703A (en) | Specific trifluoroethyl quinoline analogues for use in the treatment of APDS | |
Chen et al. | A DNA/DMXAA/Metal–Organic Framework Activator of Innate Immunity for Boosting Anticancer Immunity | |
Yamaki et al. | Remission of food allergy by the Janus kinase inhibitor ruxolitinib in mice | |
Han et al. | A deep insight into regulatory T cell metabolism in renal disease: facts and perspectives | |
WO2020056410A1 (en) | Compositions and methods for modulating immunosuppression | |
JP2009503061A (en) | Glucosamine or a derivative thereof useful as a transglutaminase inhibitor | |
Karl et al. | T-cell metabolism in graft versus host disease | |
Zhao et al. | Novel phloroglucinol derivative Compound 21 protects experimental autoimmune encephalomyelitis rats via inhibiting Th1/Th17 cell infiltration | |
CA2435739A1 (en) | Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function | |
Iannitti et al. | Clinical use of immunosuppressants in Duchenne muscular dystrophy | |
BR112020017253A2 (en) | BINDERS FOR GM-CSF OR GM-CSF RECEPTOR FOR USE IN TREATING A HEMATOLOGICAL MALIGNITY IN A PATIENT SUBJECT TO ALLO-HCT | |
Yong-Gang et al. | Combination of N-(3׳, 4׳-dimethoxycinnamoyl) anthranilic acid with cyclosporin A treatment preserves immunosuppressive effect and reduces the side effect of cyclosporin A in rat | |
Wang et al. | Chronic rapamycin treatment exacerbates metabolism and does not down-regulate mTORC2/Akt signaling in diabetic mice induced by high-fat diet and streptozotocin | |
EP3632446B3 (en) | Immunoablative therapies | |
He | A Novel Prophylactic Strategy to Minimize Stem Cell Transplantation-Related Complications | |
Burk et al. | Metabolic instruction of the graft-versus-leukemia immunity | |
EA043659B1 (en) | IMMUNOABLATIVE THERAPIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19861015 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19861015 Country of ref document: EP Kind code of ref document: A1 |